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EV biology and to newcomers who will encounter this universal cell biological system. Therefore, here we
address the molecular contents and functions of EVs in various tissues and body fluids from cell systems to
organs. We also review the physiological mechanisms of EVs in bacteria, lower eukaryotes and plants to
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E
xtracellular vesicles (EVs) are membrane-con-
tained vesicles released in an evolutionally con-
served manner by cells ranging from organisms
such as prokaryotes to higher eukaryotes and plants
(Fig. 1). The significance of EVs lies in their capacity to
transfer information to other cells thereby influencing the
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recipient cell function. EV-mediated signals can be
transmitted by all the different biomolecule categories 
protein, lipids, nucleic acids and sugars  and the uni-
que package of this information provides both protection
and the option of simultaneous delivery of multiple dif-
ferent messengers even to sites remote to the vesicular
origin.
While intensive investigation is targeted towards eluci-
dating the role of EVs in intercellular communication in a
range of pathological processes, research on EV-mediated
maintenance of homeostasis and regulation of physiolo-
gical functions remains less studied. Here, another sig-
nificant role of EVs has emerged in the removal of
unwanted molecular material as a means for cell main-
tenance. As a part of the European COST action initiative
‘‘Microvesicles and Exosomes in Disease and Health’’
(ME-HaD), here we aimed to review the current knowl-
edge and understanding of the physiological roles of EVs
in various tissues and cell systems of higher organisms,
lower eukaryotes, bacteria and plants and show how this
emerging data highlight the functional uniformity of this
cellular communication system.
During the course of evolution, both prokaryotes and
eukaryotes have developed elegant cell-to-cell communi-
cation strategies. These strategies have, for instance, helped
bacteria to coordinate their social group activities by
monitoring the environment and influencing the behaviour
of other bacteria, a process known as quorum sensing (1).
These strategies also assist multi-cellular organisms to
function as a system, for example, in pathogen interactions
with hosts. Classically in cell biology, eukaryotic cells
communicate with each other through direct interaction
(juxtacrine signalling) and/or by secreting soluble factors
such as hormones, growth factors and cytokines. These
soluble factors can act on the cell itself (autocrine signalling)
or have an impact on both neighbouring (paracrine sig-
nalling) and distant cells (endocrine signalling). The direct
cell-to-cell signalling can be mediated by a membrane-
anchored stimulus, deciphered by receptors located in
other cells, or by junctional complexes including tight
Fig. 1. Biogenesis and release of extracellular vesicles.
Extracellular vesicles can be broadly classified into 3 main classes: (a) Microvesicles/microparticles/ectosomes that are produced by
outward budding and fission of the plasma membrane; (b) Exosomes that are formed within the endosomal network and released upon
fusion of multi-vesicular bodies with the plasma membrane; and (c) Apoptotic bodies are released as blebs of cells undergoing
apoptosis. Lower organisms, such as bacteria and parasites, are also able to secrete EVs. Outer membrane vesicles (OVM) are formed
by outward bulging of the outer membrane of gram-negative bacteria. EEearly endosome; MVBmulti-vesicular body;
ILVintraluminal vesicles; NNucleus; OMouter membrane; Ppperiplasm; IMinner membrane; nnucleoid; Fflagella.
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junctions, desmosomes, adherens and gap junctions.
Interestingly, during the past decade, EVs have become
recognized as potent vehicles of intercellular communica-
tion in different model systems (both prokaryotes and
eukaryotes).
A brief history of EVs
The first observations of EVs and their relevance occurred
somewhat simultaneously in various physiological settings
without the realization that this form of function or
communication is a universally shared cell biological
property. Specifically, EVs were observed as procoagulant
platelet-derived particles in normal plasma, originally
reported in 1946 by Chargaff and West (2) and referred
to as ‘‘platelet dust’’ by Wolf in 1967 (3). Early observa-
tions also included matrix vesicles identified during bone
calcification by Anderson in 1969 (4). In the 19701980s,
separate independent EVobservations included the release
of plasma membrane vesicles from rectal adenoma micro-
villus cells (5), reports on virus-like particles in human cell
cultures and bovine serum (6,7) and the detection of
vesicles, later termed prostasomes (8), in seminal plasma
(9). Around the same time the first observations of tumour
originating membrane fragments were made (10), and they
were also shown to be procoagulant (11). In 1983, detailed
ultrastructural studies showed that vesicles are also
released by multi-vesicular bodies (MVBs) fusing with
the cell membrane during the differentiation of imma-
ture red blood cells (1214). More than a decade later,
Raposo and colleagues demonstrated that these vesicles,
then termed exosomes, isolated from EpsteinBarr virus-
transformed B lymphocytes, were antigen-presenting and
able to induce T cell responses (15). In 20062007, with the
discovery that EVs contain RNA, including microRNA,
EVs acquired substantially renewed interest as mediators
of cell-to-cell communication (16,17). Advancing on these
pioneering studies, EVs have been isolated from most cell
types and biological fluids such as saliva, urine, nasal and
bronchial lavage fluid, amniotic fluid, breast milk, plasma,
serum and seminal fluid (1823) (see Functions of EVs
present in body fluids section). An important step in the
recent developments of the EV field has also been the
enthusiastic collaborative work since 2011 by the members
of the International Society of Extracellular Vesicles
(ISEV: www.isev.org/), with the aim to unify the nomen-
clature and the methodologies of EVs.
The accumulating data have indicated that the contents,
size and membrane composition of EVs are highly het-
erogeneous and dynamic and depend on the cellular
source, state and environmental conditions. At present,
at least 3 main subgroups of EVs have been defined (24): (a)
apoptotic bodies, (b) cellular microparticles/microvesicles/
ectosomes and (c) exosomes (Fig. 1). Apoptotic bodies
are released when plasma membrane blebbing occurs
during apoptosis and are therefore excluded from this
review. The second vesicle group comprises vesicles of
different sizes that pinch directly off the plasma membrane.
Finally, exosomes are intraluminal vesicles (ILVs) con-
tained in MVBs, which are released to the extracellular
environment upon fusion of MVBs with the plasma
membrane. The biogenesis and secretion of EVs has
recently been extensively reviewed elsewhere (25).
Specific characteristics have been proposed for these
subgroups of EVs in some instances, but currently
there is still a lack of widely accepted specific markers to
distinguish these populations (26,27). This may partly be
explained by the lack of standardization of both isolation
procedures and methods for the characterization of EV
subgroups. In addition, isolation procedures typically do
not unequivocally purify specific types of vesicles but, in-
stead, yield complex mixtures. However, sub-fractionations
of EV subgroups may potentially be achievable by the
application of forms of affinity chromatography, employ-
ing antibodies against known or suspected EV surface
markers (28,29), or using ligands (e.g. heparin) reactive
with EV surfaces (30). Other means of sub-fractionation
being investigated include forms of charge separation or
isoelectric focusing (31,32) or by size (along with other
chemical characteristics) by field flow fractionation tech-
niques (33). As indicated above, the content of EV sub-
fractions vary depending on the source of the EVs and
their original isolation or enrichment techniques. So far,
there are few studies detailing fractionation of EV
subgroups with subsequent in-depth characterizations.
To unify the nomenclature throughout this review we
will, therefore, use the term EVs for all types of vesicles, but
include the nomenclature used in the original work where it
carries a specific significance for the context.
Molecular properties of EVs
Proteins and protein-associated functions of EVs
Proteomic studies of EVs released by primary cell cultures,
cell lines, tissue cultures or isolated from biofluids have
yielded extensive catalogues of the protein abundance
in different types of EVs. Public on-line databases are
available that catalogue EV-associated components. These
include Vesiclepedia (www.microvesicles.org/) (34), EVpedia
(www.evpedia.info) (35) and ExoCarta (www.exocarta.
org) (36).
EVs contain proteins that are considered to be pan-EV
markers (i.e. common for most EVs), and their proteins
and protein post-translational modifications that specifi-
cally reflect the vesicle localization, cellular origin and
mechanism of secretion (3740). In general, EVs are highly
abundant in cytoskeletal-, cytosolic-, heat shock- and
plasma membrane proteins, as well as in proteins involved
in vesicle trafficking. Intracellular organelle proteins are
less abundant. Proteomic profiles obtained have been
found to be highly dependent on how EVs were isolated.
Marı´a Ya´n˜ez-Mo´ et al.
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Different methods yield EVs and EV sub-fractions of va-
riable homogeneity, which makes it difficult to extrapolate
findings between different proteomic studies of EVs.
While protein profiles may be characteristic of differ-
ent EV subgroups, there is, nevertheless, no single marker
that can uniquely identify EVs. These vesicles are best
isolated, defined and characterized based on multiple
techniques. These include isolation by differential ultra-
centrifugation, density gradient centrifugation (sucrose or
iodixanol gradients), filtration and size-exclusion chro-
matography. Due to the small differences in physical
properties and composition, discrimination between dif-
ferent EV subgroups after their cellular release remains
difficult. Furthermore, the same cell type may secrete dif-
ferent subgroups of vesicles depending on environmental
factors (e.g. oxygen tension), cell topography (e.g. from
basolateral or apical cell surfaces) (41) or activating sti-
mulus (e.g. apoptosis or autophagy) (42). In addition, the
protein contents of the same EV subgroups are regulated
based on activatory stimulus (43). Further, a given
cell may contain different types of MVBs characterized
by differential exosome content (44,45). Characterization
of EV protein content is commonly conducted by, for
example, immunoblotting, immuno-gold labelling com-
bined with electron microscopy and antibody-coupled
bead flow cytometry analysis. Proteins enriched in EV
sub-populations that are often used as markers (although
not necessarily specific) include tetraspanins (CD9,
CD63, CD81 and CD82), 14-3-3 proteins, major histo-
compatibility complex (MHC) molecules and cytosolic
proteins such as specific stress proteins (heat shock
proteins; HSPs), Tsg101 and the Endosomal Sorting
Complex Required for Transport (ESCRT-3) binding
protein Alix (46). Tetraspanins CD9, CD63 and CD81
were previously considered to be specific markers for
exosomes; however, these proteins have now also been
observed in apoptotic bodies and microvesicles (41,47).
Conversely, some studies indicate that CD63 (and Tsg101)
are only present in certain EV subgroups (48). Overall,
CD9 and CD81 belong to the top 200 most frequently
identified EV proteins (35). A consensus on isolation
procedures and additional experimental data are required
to determine if there are indeed specific proteins to be
associated with specific EV-subgroups (41).
Protein glycosylation and lectins
The first comprehensive insight into the glycome of EVs
was obtained by lectin-microarray analysis of EVs from T
cells. Their glyco-pattern was found to be distinct from
that of the parent cell membrane (49). EVs were enriched
in highly mannosylated epitopes, including complex N-
glycans, N-acetyl lactosamine, sialylated and fucosylated
epitopes, while blood group antigens A/B were excluded.
The same distinctions from parent cell membranes were
found in the EVs from a series of human cell lines (T cells,
melanoma and colon cancer) (50). Lectin-binding pat-
terns were found to be conserved in all the EVs examined,
although binding of a given lectin was associated with
different proteins. Glycosylation was found to be dif-
ferent between exosomes and apoptotic bodies (37).
Several studies reported changes in the glycosylation pat-
terns of EVs in pathological conditions including ovarian
cancer (37), classical galactosaemia (51) and polycystic
kidney disease (52), pointing out the important role of
glycosylation in EV (patho) physiology.
Studies using classical biochemical techniques and
proteomic profiling of EVs have revealed the presence of
several glycan-binding proteins. These may be particularly
relevant to which cells EVs will be targeted and how they
interact with those target cells. As an example, the C-type
P-selectin (CD62), which is present on the surface of EVs
released from activated platelets, allows EVs to bind to
target cells via its classical P-selectin glycoprotein ligand-1
(PSGL-1) ligand (53). Also, B cell-derived EVs were found
to be enriched with a2,3-linked sialic acid allowing their
capture by sialoadhesin (CD169, Siglec1) on macrophages
(54). Proteomic profiling of EVs derived from human
plasma revealed 9 lectins including collectin sub-family
member 10 (COLEC10), ficolin 1, 2 and 3 precursors,
mannose-binding lectin serine protease 1 and 2 precursors
(55). The presence of osteosarcoma amplified-9 endoplas-
mic reticulum lectin and mannose-binding lectins in saliva
(56), plasma (55) and urine (18,38) EVs has been reported.
Intelectin-1, a galactofuranose-binding lectin, was found
in the urinary EVs (56). The lectin galactose binding
protein-3 (LGALS3BP), that binds galectin 3, was pre-
dominantly found in EVs derived from prostate (57) and
ovarian cancer cell lines (58).
Galectins are a family of soluble lectins characterized
by their affinity for beta-galatosides in the absence of
divalent cations. EVs derived from bladder cancer (59)
were reported to carry galectin-1 and galectin-3; the
latter was also detected in EVs derived from saliva (60),
parotid gland (56), conditioned medium from the human
colon cancer cell line LIM1215 (28), urine (18,38) and
plasma (55). Galectin-4 has been detected in EVs secreted
by human colorectal cell line HT 29 (61) and colon
tumour cell line LIM1215 (28), while galectin-5 on the
surface of EVs from reticulocytes was found to be crucial
for EV uptake by macrophages (62). Finally, galectin-7
has been detected in EVs derived from human parotid
saliva (56).
The importance of glyco-interactions in EVs sorting and
EVs effect on target cells is supported by recent studies
(63,64). Moreover, surface glycosylation patterns may be
important for the EV uptake by recipient cells (37,50,62),
which has been shown to be dependent on heparin sulphate
proteoglycans (65) so that it can be inhibited by heparin
addition (30).
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Molecule sorting to EVs
The common protein signature of different kinds of EVs,
which is likely to be crucial for their function and may
relate to their biogenesis, may also be connected to
membrane curvature (Fig. 2). Membrane constituents
are more or less free to move laterally over the membrane,
so molecules with a given effective shape will accumulate
in regions that are energetically favourable (66), deter-
mining the local membrane composition and its curva-
ture (i.e. shape). Curvature-based sorting of proteins
(67,68) and lipids (69,70) has been studied in artificial
and eukaryotic membranes and it has been established
that bacteria are capable of sorting macromolecules to
distinct sub-cellular domains (71,72).
This self-consistent mechanism of the curvature sorting
of membrane constituents (73) begins in the parent cell
during the membrane budding. It largely determines the
shape, size and composition of the EV and consequently
influences their physiological role. The mechanism is non-
specific; it takes place in all membrane types and applies
to vesicles formed either inside the MVB or by budding
from the plasma membrane. Thus, this mechanism implies
that several structural components are shared among
different kinds of vesicles.
Some membrane constituents such as lectins (50) and
tetraspanin-enriched microdomains (74,75) have already
been reported to play a crucial role in the concentration
of EV protein components and, at the same time, in
the recruitment of structural and shaping components.
Curvature-induced sorting of membrane constituents and
their direct interactions may lead to the formation of
lateral microdomains with specific composition such as
tetraspanin-enriched microdomains (76) and membrane
rafts (77) (Fig. 2). Tetraspanins have been proposed to
induce membrane curvature (78) and incorporation of the
membrane receptors into tetraspanin-enriched microdo-
mains has been shown to be relevant for their routing
towards exosomes (74,75,79). Analysis of ganglioside
GM1 and the cytosolic protein content of erythrocyte
membrane buds and the released vesicles have shown a
redistribution of these molecules with respect to the parent
cell membrane. This indicated that entire microdomains
may be sorted to relatively flat membrane regions or to
highly curved ones (that eventually become EVs), depend-
ing on their intrinsic molecular shape and/or interactions
between the microdomain elements (73). Among the
curvature-favouring structural components, the BAR
(Bin/Amphiphysin/Rvs) domain-containing proteins were
shown to drive the formation of tubular and vesicular
membrane structures (80,81). The ESCRT proteins seem
to favour the neck region of the forming EVs (82,83), where
they play an important role in the fission of membrane
buds (84,85). Besides the morphological arrangement of
membranes to induce the formation of ILVs in MVBs (86),
the ESCRT complex recruits exosomal cargo components
through the binding to ubiquitinilated proteins. Incor-
poration of a given protein into EVs may depend on the site
of vesicle generation (plasma membrane versus MVB) and
follow either an ESCRT-dependent or -independent path-
way. Intraluminal components of the EV membrane, for
Fig. 2. Curvature sorting mechanism.
In the process of budding, membrane constituents redistribute to regions with fitting membrane curvature to minimize membrane free
energy. Redistribution of membrane constituents is then reflected in the pinched off vesicles. As examples, this scheme indicates
tetraspanins, ESCRT (Endosomal Sorting Complex Required for Transport) complexes, anonymous integral membrane proteins of a
given type, glycoproteins and proteins that are preferentially located in the cell interior and exterior. ESCRT complex favours the neck
region of the bud and is disintegrated after the vesicle pinches off. The content that is enclosed by the vesicle membrane becomes mobile
and may reach distant cells.
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example, cytoskeletal adaptor molecules, may also have a
role in both editing and maintaining the morphology of the
vesicles. The post-synaptic density protein, disc-large,
zonulin I (PDZ) protein syntenin was reported to be
necessary for the formation of MVB ILVs and, therefore,
exosomes (87,88). Proteins of the ERM (Ezrin, Radixin
and Moesin) family are highly enriched in EVs and have
been linked to different componentswithin the tetraspanin-
enriched microdomains (74,89). Insertion into membrane
microdomains may also influence the degree of oligomeri-
zation, which may also function as a targeting mechanism
(90,91). All these studies suggest that local protein and, as
described below, also lipid sorting within the membrane is
closely connected to the formation and identity of EVs.
Uptake mechanisms
Due to their extensive and variable protein content, EVs
may be considered as vectorial signalosomes (92). The
protein composition of EVs may determine their function-
ality in several different ways. Surface-exposed receptors
and ligands are responsible for biodistribution, for the
binding of EVs to target cells or to the extracellular matrix.
Subsequently, EVs may trigger intracellular signalling
pathways through a simple interaction with the surface re-
ceptors or ligands of target cells or by undergoing inter-
nalization. In addition, EVs may induce changes in the cell
phenotype by transfer to the target cell of functionally
active receptors such as CCR5 (93), EGFRvIII (94) or
MET (95).
EV uptake by target cells appears to depend on the type
of recipient cells. In most instances, EV uptake seems to
occur through phagocytosis (65,96) and its extent may
depend upon the phagocytic capabilities of the recipient
cell (97). Macropinocytosis may represent an alterna-
tive way through which EVs may transfer their content
(98100). As membrane fusion requires a similar fluidity
between the 2 fusing membranes, and both EVs and
plasma membranes display the same fluidity at pH 5.0
(101,102) but not at neutral pH (which makes the
membrane more rigid) (103), the direct fusion of EVs
with the plasma membrane may be limited to acidic pH
conditions such as those found inside a tumour (99). It is
noteworthy that MVBs have a pH of 5, and that the
fusion of the ILVs to the MVB-limiting membrane (i.e.
back fusion) has also been reported to occur (104). The key
influence of the microenvironment’s pH suggests that the
differences in the electrostatic charges between EVs and
the plasma membrane of the cells should be considered in
relation to the physiological roles of EVs.
It is conceivable, therefore, that when a functional
molecule is delivered by EVs it may be more active than
in its soluble form. One clear example of this is the ligands
for death receptors, which are more functional when
expressed on a membrane than in their soluble form
(105,106). Furthermore, proteomic analyses have revealed
that both cell surface-anchored and soluble matrix metal-
loproteinases are present in EVs from cell cultures and
body fluids (107). Some of these metalloproteinases were
proteolytically active, suggesting that they may alter the
EV content; directly interact or cleave extracellular matrix
proteins; or shed membrane-anchored receptors from
target cells.
Biodistribution and targeting
The steady-state level of EVs in circulation reflects a
balance between the EV generation and their clearance.
Independent studies indicate that the half-life of purified
exogenous EVs, artificially introduced into circulation, is
very short. Biotinylated rabbit EVs were cleared in rabbit
circulation in 10 min (108). EVs from splenocyte
supernatants (54), red blood cell-derived EVs (109) and
EVs from B16 melanoma cells (110) all showed a
clearance of more than 90% after 30 min. However,
human platelet concentrate-derived EVs remained in the
circulation with a half-life of 5.5 hour (111). As EVs may
show protection from complement-mediated lysis due
to expression of glycosylphosphatidylinositol (GPI)-
anchored CD55 and CD59 (112), their clearance from
circulation is most likely due to retention and uptake in
target organs. Indeed, a biodistribution study with red
blood cell-derived EVs showed an uptake by the liver
(44.9%), bone (22.5%), skin (9.7%), muscle (5.8%), spleen
(3.4%), kidney (2.7%) and lung (1.8%) (109). In contrast,
melanoma-derived EVs were mainly taken up by lungs
and spleen (110). Biodistribution of EVs most probably
depends on the parent cell source, as well as the
availability of different target cell types to internalize the
circulating EVs. More detailed studies comparing differ-
ent injection sites, donor cells and healthy and disease
conditions are necessary to establish the clearance and the
organ uptake of the various EV populations.
Targeting by specific adhesion molecules determines EV
biodistribution. Sialic-acid-binding immunoglobulin lec-
tins (siglec) are expressed on a variety of leukocytes, and
CD169 (sialoadhesin) preferentially binds to a2,3-linked
sialic acids which decorate proteins on the surface of EVs.
Indeed, B cell-derived EVs are captured by CD169-
expressing macrophages in both spleen and lymph nodes
(54). In CD169 knock-out mice, EVaccess to the lymphoid
system is dysregulated, resulting in aberrant trafficking of
EVs into the splenic red pulp or lymph node cortex (54).
Another insight into the potential influence of saccharides
came from the finding that EV uptake by dendritic
cells (DCs) was reduced in the presence of D-mannose or
D-glucosamine (113), suggesting an EV uptake mecha-
nism is based on the C-type lectin interaction. In addition,
b-galactosides on reticulocyte EV surfaces may be in-
volved in their uptake by macrophages through interaction
with galectin-5 (62). However, sugars do not seem to play
a significant role in the EV interaction and their uptake,
Biological properties of EVs and their physiological functions
Citation: Journal of Extracellular Vesicles 2015, 4: 27066 - http://dx.doi.org/10.3402/jev.v4.27066 7
(page number not for citation purpose)
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ity
 of
 Sz
eg
ed
] a
t 1
0:0
2 0
7 N
ov
em
be
r 2
01
7 
at least in the in vitro studies with the SKOV-3 ovarian
carcinoma cell line (37), suggesting cell- or condition-
specific differences in the uptake mechanisms.
Lactadherin (also known as milk fat globule-epidermal
growth factor 8) binds phosphatidylserine (PS) on the
surface of apoptotic cells and platelet-derived EVs
(114,115). Upon binding, a conformational change ex-
poses the ArgGlyAsp (RGD) motif, which then binds to
avb3 and avb5 integrins, subsequently promoting EVs
phagocytosis by macrophages (115). Thus, lactadherin
bridges the binding of PS-positive EVs to the splenic
macrophages, enabling their removal from the circulation
(114). Similarly, developmental endothelial locus-1 (Del-1)
also mediates binding to both PS on the platelet-derived
EVs and avb3 integrin on endothelial cells (ECs) (116).
Both the interaction and the capture of EVs by cell
surfaces are highly facilitated by the reciprocal expression
of intercellular adhesion molecules, such as ICAM-1 and
LFA-1 integrin (117119).
Interaction with membrane receptors
EVs can interact with target cells through a ligand-to-
receptor interaction. Specific EV proteins such as MHC I
and II (119124), transferrin receptors (125) and tet-
raspanins (74,75) are active in the downstream signalling
pathways of target cells by triggering, for example,
integrins and calcium signalling (126), mitogen-activated
protein kinase (MAPK) activation (125) or natural killer
group 2D (NKG2D) signalling (127,128).
Among ligand-to-receptor interactions, noteworthy are
those between some HSPs, such as HSP60 and HSP70, and
a number of membrane receptors present mainly on
immune cells, such as CD14, CD91, Toll-like receptor
(TLR)-2, TLR-4 and LOX-1 (129), as well as CD94/CD56
(130). In particular, some HSPs such as HSPs 27, 60, 70
and 90 can be intracellularly redistributed from their
canonical sites to plasma membrane, lipid rafts and
MVBs in some pathological conditions such as cancer. In
turn, they are secreted via EVs in which they are localized
at membrane level (31,32,131,132). As a consequence, their
binding to these receptors may be of relevance for the
interaction between EVs and target cells during these
diseases.
It is, however, likely that the enrichment in signalling
molecules alone is insufficient for facilitating the signal-
ling functions of EVs. In fact, EVs also contain active
lipolytic moieties, such as phospholipases, leading to the
formation of bioactive lipid mediators (fatty acids and
prostaglandins), which may interact with peripheral G-
protein-coupled receptors and the nuclear receptors in
target cells (133).
A clear example of the functional role of EVs ligands for
membrane receptors is the presence of ligands for death
receptors in EVs. It has been shown that human natural
killer (NK) cells release EVs that express both NK cell
markers and cytotoxic molecules such as FasL and per-
forin (134). Incidentally, this is also evident for other
cytotoxic cells as well (135). These EVs were released in the
extracellular milieu and could be detected in the circula-
tion. The NK-derived EVs are fully active in inducing cell
death of target cells. Moreover, human tumour cells release
EVs expressing ligands for death receptors, including FasL
and TNF-related apoptosis-inducing ligand (TRAIL).
These EV-associated ligands are fully functional in indu-
cing death receptor-mediated cell death. Intriguingly, the
FasL- and TRAIL-bearing EVs released by malignant
tumour cells may participate in lysing lymphocytes
that should kill the tumour cells, while being unable to
trigger cell death in the EV-releasing parent tumour cells
(136,137).
EV-associated cytokines
Besides mediating exchange of intercellular information
by their surface molecules, EVs have been shown to be
carriers of important soluble mediators, such as cytokines.
For cytokines that lack an N-terminal signal peptide,
release by EVs represents a form of leaderless secretion.
Examples of EV-associated or -secreted cytokines are
given in Table I.
The best-known example of the involvement of EVs in
the cytokine transport is interleukin 1b (IL-1b). IL-1b is
not only released by cells upon the fusion of secretory
lysosomes with the plasma membrane, but it is also
secreted by EVs (138,139). Once IL-1b-containing EVs
are secreted, their cytokine cargo is released into the
extracellular space upon binding of ATP to P2X7R on
the EVs (140). Another member of the IL-1 family, IL-
1a, has been found in EC-derived apoptotic bodies both
in its precursor and mature forms (141).
Similar to IL-1b, the leaderless cytokine IL-18, which is
also secreted upon inflammasome activation, was shown
to associate with EVs shed from the surface of macro-
phages (142). Macrophage migration inhibitory factor
(MIF) (143) and IL-32 (144) represent other examples of
EV-associated cytokines undergoing an unconventional
secretion in the absence of a signal peptide. Membrane-
bound tumour necrosis factor (TNF) was demonstrated to
be secreted by EVs (145), mast cells release vesicular IL-6
upon IL-1 stimulation (146), while platelets liberate
vascular endothelial growth factor (VEGF)-containing
EVs (147). VEGF was also shown to be present in tumour-
shed EVs, and it was released from EVs in a bioactive
form only at acidic pH characteristic for the tumour
microenvironment (148).
Chemokines constitute a highly significant and distinct
category of cytokines. Among chemokines, IL-8 (CXCL8)
and fractalkine (CX3CL1) were found to be associated
with EVs (149,150), while EVs from heat-stressed tumour
cells were associated with CCL2, CCL3, CCL4, CCL5 and
CCL20 (151).
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Regarding regulatory cytokines, thymus-derived EVs
were shown to induce regulatory T cells via vesicle-
associated Transforming Growth Factor (TGF) b (152).
Also, tumour-derived EVs were found to use a TGFb-
mediated mechanism to induce regulatory Tcells (153,154)
and myeloid suppressor cells (155). While the nature of the
cytokine association with the various EVs in general is
poorly understood, the role of heparan sulphate proteo-
glycans in tethering TGF-beta to the vesicle membrane,
and its functional handover to recipient cells, has been
reported (156,157). However, in fact, no systematic studies
have been conducted to determine the complete spectrum
of EV-associated cytokines. Furthermore, the extent to
which vesicular localization of cytokines affects conven-
tional cytokine measurements remains a key issue that has
yet to be addressed.
RNA composition
Extracellular RNA exists in different forms. It may be
enclosed in EVs, bound in protein complexes or exist in
freely circulating form. The presence of functional RNA in
EVs was first described in 2006 for murine stem cell-
derived EVs (17) and in 2007 for murine mast cell-derived
EVs taken up by human mast cells (16). While cellular
mRNA varies in size from 400 to 12,000 nucleotides (nt),
RNA detected in EVs has a predominant size of B700 nt
(158,159). EVs, however, do contain intact mRNA (160),
mRNA fragments (159), long non-coding RNA (161,162),
miRNA (163,164), piwi-interacting RNA (161), ribosomal
RNA (rRNA) (161) and fragments of tRNA-, vault- and
Y-RNA (165,166). Most studies report absence or minor
amounts of ribosomal 18S and 28S in EVs, as opposed to
their abundant intracellular presence (e.g. 16,47,161,166).
Some studies do, however, report of a substantial proportion
of rRNA (87%) in this EV sub-group (167) and others
have reported large amounts of rRNA fragments based on
next-generation sequencing (168). Thus, variability can
exist depending on the EV source and the methodology
used to obtain the data. Verification of the intraluminal
localization of RNA in EVs, rather than in free circulating
form, is mostly conducted by RNaseA treatment of EV
(47,169). However, some studies have reported that protein
interaction with Ago2 may also provide resistance to
RNaseA (170), so that a pre-treatment with proteinase
K, which renders AGORNA complexes susceptible to
RNAse degradation, should also be performed (171).
An enrichment of 3?UTR mRNA fragments, rather
than intact mRNA molecules, in EVs has been reported
(159). As the 3?UTR contains multiple sites for regulatory
miRNA binding, this suggests that the RNA of EVs may
compete with cellular RNA for binding of miRNAs or
RNA-binding proteins in the recipient cells so as to
regulate stability and translation (159). The release of
specific RNA molecules may also have intrinsic effects on
the regulation of gene expression in the parental cells (172).
MicroRNAs (miRNAs) are 21 nt regulatory mole-
cules that are transcribed as hairpin precursors (pri-
miRNAs), cleaved by Dicer (into pre-miRNAs), bound
by Argonaute proteins (Ago) and loaded into the miRNA-
induced silencing complex (miRISC) for mRNA tar-
get regulation. miRNAs are secreted both in EVs and in
a non-vesicular form. When released as soluble protein-
complexes molecules, miRNAs have been detected in com-
plexes with the Ago2 protein or high-density lipoprotein
(HDL) (173175).
Some studies report absence of miRISC complex
proteins (including Ago2) in the exosomes sub-group of
Table I. Examples of EV-associated cytokines
Cytokine Secreting cells Ref.
Interleukin 1b (IL-1 b) Secreted not only by fusion of secretory lysosomes with the plasma
membrane but also by EVs
(138140)
Interleukin 1a (IL-1 a) Endothelial cell-derived apoptotic bodies, both in precursor and
mature forms
(141)
Interleukin 18 (IL-18) Associated with EVs shed from the surface of macrophages (142)
Macrophage migration inhibitory factor (MIF) Associated with EVs that are transferred to spermatozoa during
the epididymal transit
(143)
Interleukin 32 Released from intestinal epithelial cells in EVs (144)
Membrane-bound tumour necrosis factor (TNF) Detected on EVs produced by synovial fibroblasts of patients
with rheumatoid arthritis
(145)
Interleukin 6 (IL-6) Released in EVs by mast cells upon IL-1 stimulation (146)
Vascular endothelial growth factor (VEGF) Secreted in EVs by platelets (147)
Interleukin 8 (CXCL8) In association with tumour-derived EVs (149)
Fractalkine (CX3CL1) Released from apoptotic lymphocytes in EVs (150)
CCL2, CCL3, CCL4, CCL5 and CCL20 Associated with EVs from heat-stressed tumour cells (151)
Transforming growth factor b (TGF b) Associated with thymus-derived EVs, tumour-derived EVs (152155)
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EVs (39), whereas others report Ago2 presence (170). In
this regard, it has been proposed that RISC proteins in
EVs could process precursor microRNAs (pre-miRNAs)
into mature miRNAs inducing cell-independent micro-
RNA biogenesis (176).
The relatively decreased levels of mRNA targets of
exocytosed miRNAs have been observed (39,172,177).
Together, these observations indicate that miRNA loa-
ding into EVs can occur independent of mRNA target
engagement and by a mechanism different from the Ago2-
complexed miRNA secretion. The observation that
miRISCs accumulate at sites of MVBs suggests that a
regulatory circuit of miRISC activity and/or miRNA
exosome loading may exist (177).
Mechanisms that control RNA-sorting to EVs
Since the discovery of RNA in EVs (16,17,178), increas-
ing evidence suggests that RNAs are not passively loaded
into EVs, but that certain populations of RNAs become
enriched in EVs compared to parental cells. Although
this enrichment could occur because of a size restriction,
there is a specific repertoire of miRNAs selectively
exported to EVs even among small RNA species, whereas
other miRNAs are usually excluded (164,166,179,180),
indicating that an active sorting mechanism occurs at
RNA level. An enrichment of RNA containing specific
nucleotide motifs has been documented in EVs (181,182).
Furthermore, the expression of cellular miRNAs or
miRNA target sequences can modulate the presence of
miRNAs in exosomes (183).
The loading of miRNAs into EVs has been shown to be
controlled by heterogeneous nuclear ribonucleoprotein
(hnRNP) A2B1 (182). hnRNPs are a family of ubiquitous
protein with roles in RNA trafficking and function.
hnRNPA2B1 recognizes the EXOmotif (GGAG tetranu-
cleotide) in miRNAs and controls the loading of these
miRNAs into EVs. hnRNPA2B1 inside the EVs is
sumoylated; this post-translational modification is neces-
sary for the loading of miRNAs into EVs. mRNA species
also show a selective enrichment into EVs. Evidence
suggest that a consensus sequence within the 3?UTR of a
number of mRNAs enriched in EVs may act as a zipcode
sequence that targets mRNAs into EVs, similar to the
EXOmotif of miRNAs. This zipcode consists of a 25 nt
sequence which contains a short CTGCC core domain on a
stem-loop structure and carries a miR-1289 binding site
(184). It has also been proposed that the addition of non-
templated nucleotides to the 3?end of the microRNA may
contribute to direct microRNA sorting into EVs (185).
Biological significance of the horizontal transfer of
mRNAs
The first experimental evidence that EVs can transfer
intact, functional mRNAs to recipient cells was gained by
the finding that the treatment of murine bone marrow
mononuclear cells with embryonic stem cell-derived EVs
enriched in Oct4 mRNA resulted in the increase of Oct4
protein expression in the bone marrow cells, while pre-
treating the EVs with RNAse abrogated this effect (17).
In turn, it was thereafter demonstrated by incubating
human mast cells with mouse mast cell-derived EVs that
the murine mRNAs could be transferred to the recipient
cells by EVs where they were translated into murine
proteins, although the EVs themselves did not have
functional machinery for the protein synthesis (16). Yet
another study showed that endothelial progenitor cell-
derived EVs could transfer functional mRNAs to micro-
vascular ECs thus triggering neoangiogenesis (186). The
transfer of functional mRNA was proved by generating
cells that express GFP mRNA but had not detectable
levels of the protein in their EVs, yet ECs treated with
these EVs started to express GFP protein (186). Taken
together, these studies provide a solid basis for the
concept that EVs transfer functional mRNAs that can
be internalized and translated in the recipient cells.
mRNA-containing EVs also have been shown to
enhance cell survival and repair of tissues under various
stress conditions (187189). Human mesenchymal stem
cell-derived EVs were found to contain 239 mRNAs, most
of which are involved in cell differentiation, transcription,
cell proliferation and immune regulation (188). Two of
these were shown to be internalized and translated into
full-length proteins in murine kidney epithelial cells in vitro
and in vivo, thus demonstrating the feasibility of a
horizontal transfer of mRNAs in this experimental setting
(187,188). Treatment of mice with these EVs protected
against glycerol or cisplatin-induced kidney injury
(187,188). Interestingly, the mRNA content of EVs is
modulated by the physiological state of the cell and stress
conditions and may play a role in the maintenance of tissue
homeostasis and synchronizing the functional state of
cells. For instance, the mRNA content was found to differ
significantly between EVs derived from mast cells grown
under oxidative stress and normal conditions (189). EVs
released under oxidative stress enhanced the ability of
untreated mast cells to handle H2O2-induced oxidative
stress, while the exposure to UV-light eliminated the
protective effect (189). Likewise, the EV-containing
mRNAs were found to be regulated by growth factor
stimulation of cardiomyocytes (190) and by hypoxia in
glioma cells resulting in the expression of a variety of
hypoxia-induced mRNAs and proteins in hypoxic glioma-
derived EVs (191). Regarding the synchronization of the
functional status of cells, EVs derived from large adipo-
cytes have been shown to transfer specific mRNAs
involved in fatty acid esterification and lipid droplet
biogenesis to small adipocytes, where they stimulated lipid
synthesis and storage (192).
All these effects are at least partially mediated by the
horizontal transfer of RNAs. However, currently it is
difficult to distinguish between the effects triggered by
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mRNAs and various non-coding RNAs that are abundant
components of exosomal RNAs (161) and to assess the
extent to which individual mRNAs contribute to these
effects. Furthermore, it is not yet clear what proportion of
a cell’s transcriptome in EVs consists of intact mRNAs
that can be translated in the recipient cells and which
mRNA fragments may play regulatory roles (159,161).
miRNA-based functions
Accumulating evidence indicates that the incorporation of
miRNAs in EVs allows those miRNAs to circulate in the
blood while avoiding degradation from blood RNAse
activity. Selective disposal of some miRNAs in EVs has
been also suggested to be a rapid way of regulating gene
expression during, for example, lymphocyte activation, as
when prompted by vaccination (193), or as a mechanism of
tumour suppressor miRNA removal in cancer (172). A
comprehensive list of miRNAs found incorporated into
EVs is available in the miRandola database (www.atlas.
dmi.unict.it/mirandola/index.html) (194) and other data-
bases such as EVpedia or Vesiclepedia. Such miRNAs may
be secreted by a range of cells, such as immune cells (164),
stem cells (195), blood cells (196) or adipocytes (192,197),
and growing evidence indicates that they may have im-
portant physiological roles [reviewed in Refs. (198202)].
At least for some cell types, miRNAs may be transferred
within EVs to neighbouring cells, where they alter the gene
expression and phenotype of the recipient cells.
EV-mediated transfer of miRNAs has been shown to
have immunological relevance (203). For example, an
antigen-driven unidirectional transfer of some miRNAs
(such as miR-335) from T cells to antigen-presenting
cells (APCs), mediated by CD63 EVs, has been dem-
onstrated to occur during immune synapses formation.
The transferred miRNAs were shown to modulate gene
expression in recipient cells (164). It has been described
that EVs released by different effector T-cell subsets
(Th1, Th2 and Treg) have different miRNA signatures
(204). The authors identified exosome-shuttled specific
miRNAs transferred from Treg that suppress pathogenic
Th1 cells and prevented inflammation. Similarly, mast
cell-derived EVs have been shown to contain miRNAs
(205) and macrophage-derived microvesicles transfer
miR-223 and induce differentiation of naive monocytes,
suggesting that an amplification loop  mediated by
EVs  may exist to enhance immune function (206).
Interestingly, high expression levels of immune-related
miRNAs (such as miR-181a and miR-17) in CD63
EVs were detected in human milk during the first
6 months of lactation (207). Deep sequencing technol-
ogy has identified many miRNAs in human breast milk
EVs with an abundance of immune-related miRNAs.
This suggests that these EV miRNAs are transferred
from the mother’s milk to the infant, possibly having an
essential role in the development of the infant immune
system (208). Placenta-specific miRNAs are also pack-
aged into EVs and may mediate cross-talk between the
feto-placental unit and the mother during pregnancy
[reviewed in Ref. (209)].
Evidence suggests that miRNAs transported by EVs
also have a physiological role in ECs. For example, the
efficacy of islet transplantation in type 2 diabetes patients
is often limited by poor graft vascularization. However,
EVs derived from the endothelial progenitor cells activate
an angiogenic programme in the islet endothelium,
mediated by the pro-angiogenic miR-126 and miR-296,
and were shown to be crucial for transplanted islet
engraftment and survival (210). During atherosclerosis,
EC-derived apoptotic bodies enriched in miR-126 are
generated and transfer paracrine ‘‘alarm signals’’ to
recipient vascular cells, inducing CXCL12-dependent
vascular protection (211). Blood cell-derived EVs, contain-
ing miR-150 (more abundant in atherosclerotic patients)
have been shown to enter endothelial HMEC-1 cells,
delivering miR-150, which reduced c-Myb expression
and enhanced cell migration of HMEC-1 cells (179). In
turn, EC-derived EVs transferred miR-143 and miR-145
to smooth muscle cells, inducing an atheroprotective
phenotype (212).
Although investigations are yet in their infancy, there
are reports showing the relevance of miRNA transfer in
several physiological settings. For instance, the transport
of miRNAs in EVs seems to function as a neuron-to-
astrocyte communication pathway in the central nervous
system (CNS) (213). Other examples are EV-mediated
transfer of miRNAs during muscle cell differentiation
(214), follicular maturation (215) or osteogenic differen-
tiation of human bone marrow-derived mesenchymal
stem cells (216). In addition, in stem cells, miR-126 in
EVs has been implicated in the regulation of hematopoie-
tic stem/progenitor cell trafficking between the bone
marrow and peripheral sites (217). In addition, EVs
from embryonic stem cells were reported to have an
abundant quantity of miRNAs which could be transferred
to mouse embryonic fibroblasts in vitro (218). Interest-
ingly, EVs derived from preosteoblasts were found to
influence embryonic stem cell differentiation and 20% of
the examined miRNAs in the EV cargo were increased
more than twofold when compared with the preosteoblast
cells (219). Despite the emerging evidence that miRNAs
transported in EVs may be responsible for intercellular
communication, it is yet to be determined if the amounts
of miRNAs required to produce that effect are adequate
to confer relevant paracrine and/or endocrine effects with
regards to physiological impact in vivo, and how common
this process is in vivo [reviewed in Ref. (220)].
DNA content of EVs
In contrast to RNA, the presence of DNA in EVs has so
far been less explored despite the early concept of the
Biological properties of EVs and their physiological functions
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presence of oncogenic DNA in apoptotic bodies (221).
Mitochondrial DNA (mtDNA), single-stranded DNA,
double-stranded DNA (dsDNA) and oncogene amplifica-
tions (i.e. c-Myc) have been detected in EVs (222226).
Migration of mtDNA may take place via EVs and, hence,
EVs may represent an alternative pathway through which
altered mtDNA can enter into other cells, favouring the
diffusion of various pathologies (223). Tumour EVs carry
DNA that reflects the genetic status of the tumour,
including amplification of the oncogene c-Myc (222).
Furthermore, DNA transfer into target fibroblasts was
achieved by EVs, where EVs stained for DNA were seen in
the fibroblast cytosol and even in the nuclei (225). The
presence of dsDNA representing the genomic DNA was
detected in EVs reflecting the mutational status of parental
tumour cells (224,226,227). It was also shown that
different EV subgroups carried different DNA cargos
(227). The fact that EV-carried DNA can be used to
identify mutations present in the parental tumour cells
illustrates its significant potential as a translational
biomarker, but the physiological significance of the
DNA cargo in EVs is currently unknown.
Lipids in EVs
The metabolomic analyses on EVs reported so far have
been focused on lipids, which are emerging as very
important players for the physiological functions of these
vesicles (Table II). The first studies addressing the lipid
composition of EVs date from more than 2 decades
ago and were performed on prostate-derived EVs (ter-
med prostasomes) found in seminal fluid (228,229). An
increasing number of studies providing lipidomic data
sets of EVs from cell lines and biological fluids of
multiple species are summarized in Table I. Several
specific lipids have been suggested to play a role in the
formation and function of EVs. Lipids have been
included in the EV databases such as Vesiclepedia (34)
and EVpedia (35), and specific reviews on EV lipids
are also available (104,230232). Although differences in
the lipid composition of EVs derived from different
sources have already been found, EVs are generally
enriched in sphingomyelin, cholesterol, PS and glyco-
sphingolipids compared to their parent cells (232). EVs
from placenta also contain an elevated proportion of
sphingomyelin and cholesterol; sphingomyelin/phospha-
tidylcholine ratio showed a unique reversal of ratio (3:1),
compared to that normally found in human cells or
plasma (233). The characteristic lipid composition of the
EV bilayer probably contributes to the stability that they
show in different extracellular environments. Therefore,
knowledge about the specific lipids that confer the
stability of EVs may be used to improve liposomal drug
delivery systems (231,234).
Lipids sorting and the role of lipids in EV biogenesis
and release
Lipids are not randomly included into EVs but, similarly
to other biomolecules, they are specifically sorted. EV
membranes are enriched in cholesterol and sphingomye-
lin, suggesting that EV membranes may contain choles-
terol/sphingolipid-enriched membrane domains similar
to raft domains (detergent-resistant membranes) (235
237). Cholesterol and long saturated fatty acids of
sphingolipids enable tighter lipid packaging of lipids
than the phospholipids, with mainly unsaturated acyl
chains found in other regions of the membrane. The high
content in sphingolipids and cholesterol provides struc-
tural rigidity to EVs and an elevated resistance to
physicochemical changes.
Several lipids have been suggested to be involved in and/
or regulate EV formation/release. Cholesterol has been
shown to regulate EV release (236,238,239). Interestingly,
cholesterol is also important for the release of several
enveloped viruses, including influenza virus and HIV-1,
which select membrane rafts and tetraspanin-enriched
microdomains as budding platforms to exit from the host
cells. In addition, membrane microdomain-associated
proteins, which are critical determinants of hostviral
interactions, are the most likely key determinants of EVs
target cell interactions. Ceramide, formed by the action of
neutral sphingomyelinase 2 on sphingomyelin, has also
been proposed to be involved in the formation of ILVs
within the MVBs (240). In addition, other lipids such as
lysobisphosphatidic acid (LBPA) and phosphatidic acid
have been suggested to be involved in the biogenesis of EVs
(232,241).
Lipid-dependent functions of EVs
Besides the essential structural role of lipids in formation
of EV membranes, bioactive lipids, such as eicosanoids,
fatty acids and cholesterol (232), can be transferred
between cells by EVs. Vesicle-bound lysophosphatidylcho-
line has been proposed to play a role in the maturation of
DCs and triggers lymphocyte chemotaxis via the G
protein-coupled receptor (103). In addition, vesicle-bound
prostaglandins triggered prostaglandin-dependent intra-
cellular signalling pathways within target cells (133) and
EV lipids impacted Notch signalling and induced cell
death in pancreatic tumoural cells (242). The angiogenic
activity of tumour-derived EVs in vitro and in vivo was
found to be mediated mainly by sphingomyelin (243). EVs
lipids may also play a role in reproduction. It has been
suggested that seminal EVs interact with sperm cells and
transfer to them particular lipids such as cholesterol that
are fundamental for the capacitation process (244,245).
Lipidomics and complete lipid profiles of EVs have
become an interesting research area in the dissection of
the biology of EVs; however, only a handful of lipido-
mes have been described to date. Since lipids are essential
Marı´a Ya´n˜ez-Mo´ et al.
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Table II. Lipidomic studies on EVs
Cell type or body fluid/species Lipid analysis Observations Ref.
Reticulocyte/Ovis aries TLC Phospholipids substantially the same as in the plasma membrane (14)
Reticulocyte/Cavia porcellus TLC Lipid composition similar to erythrocyte membranes, although
the phosphatidyl-ethanolamine content is significantly lower
(691)
B lymphocyte cell (RN HLA-DR15)/
Homo sapiens
TLC B cell-derived EVs enriched in cholesterol, sphingomyelin and
ganglioside GM3
(692)
Dendritic and mast cell (RBL-2H3)/
Homo sapiens and Rattus
norvergicus, respectively
LCFD;
GCFID
Specific lipid composition and an unusual membrane
organization
(102)
Mast cell (RBL-2H3)/Rattus
norvergicus
LCFD Phospholipase D2, enriched on EVs and its activity correlates
with the amount of EVs
(101)
Mast cell (RBL-2H3)/Rattus
norvergicus
FD Two sub-populations of EVs: one enriched in lipids from the
Golgi and the other enriched in lipids from granules
(693)
Oligodendroglial precursor cell
(Oli-neu)/Mus musculus
LCMS EVs enriched in ceramide, which triggers budding and
release reduced by inhibition of neutral sphingomyelinase 2
(240)
Melanoma cell (Mel1)/Homo sapiens TLC Comparison between EVs and cells in different pH conditions
showing that acidic EVs are enriched in SM and ganglioside
GM3, which may positively affect their fusion ability
(99)
Mast cell (RBL-2H3)/Rattus
norvegicus
GCFID;
GCMS
Phospholipases and prostaglandins which
may be activated
(133)
Reticulocyte/Rattus norvegicus TLC Changes in the lipid composition during their differentiation
parallel their physical properties
(375)
Pancreatic cancer cell (SOJ-6)
Homo sapiens
GC Enrichment in cholesterol and SM and depletion of phospholipids
may induce cell death
(242)
Monocyte-derived
macrophages/Homo sapiens
LCMS A characterization of lipidomes showing that EVs facilitate HIV-1
infection
(694)
Paracoccidioides brasiliensis LCMS;
GCMS
Identification of 33 species of phospholipids, besides fatty
acids and neutral glycosphingolipids in EVs from the
pathogenic phase of Paracoccidioides brasiliensis.
(695)
Several prostate cancer
cells/Homo sapiens
LCMS Comparison of the lipid content of EVs and their parent
prostate cell lines
(57)
Prostate cancer cell (PC-3)/
Homo sapiens
LCMS Lipidomics of EVs from PC-3 cells. EVs are highly enriched in
glycosphingolipids, sphingomyelin, cholesterol and
phosphatidylserine
(696)
Semen/Homo sapiens TLC;
GCFID
Very high cholesterol/phospholipid ratios are detected in
prostasomes isolated from human semen. The molar ratio of
cholesterol/sphingomyelin/glycerophospholipids is 4:1:1
(229)
Semen/Homo sapiens TLC;
GCFID
The fatty acid pattern in prostasome lipids is different from lipids
in the sperm membrane. Fusion between prostasomes and
sperm may stabilize sperm plasma membrane by enriching
it in cholesterol, sphingomyelin and saturated glycerophospholipids
(228)
Semen/Equus ferus caballus TLC;
GCFID
Comparison of the lipid compositions of equine and human
prostasomes and how lipids may be connected to the different
reproductive physiology of these species
(697)
Semen/Sus scrofa TLC Boar prostasomes contain large amounts of cholesterol and
phospholipids
(698)
Semen/Homo sapiens Characterization of the lipid content of 2 prostasome populations.
Both types had an unusual lipid composition, with high levels of
sphingomyelin, cholesterol and glycosphingolipids
(333)
Plasma/Homo sapiens TLC Microparticles from plasma contained a high level of
phosphatidylcholine (59%), sphingomyelin (21%) and
phosphatidylethanolamine (9%)
(699)
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structural and functional constituents of EVs, additional
lipidomic studies of EVs from different cell types and body
fluids are required to elucidate the role of lipids in the
biogenesis and biological functions of EVs. Furthermore,
given the absence of information related to other meta-
bolites distinct from lipids, metabolomic studies should
also be extended to non-lipid analytes to obtain a more
comprehensive picture of the small molecule composition
and function of EVs.
Physiological functions of EVs in mammals
Functions of EVs present in body fluids
Body fluid-derived EVs are a mixture of vesicles originat-
ing from different sources such as the cells found in the
body fluids and/or the cells lining the cavities of extruded
body fluids (Fig. 3). The lipid membrane of EVs encapsu-
lates and protects their contents from the degra-
ding enzymes present in the body fluids and thus, protects
them as a source of physiological and pathological in-
formation, which can be sent over a distance. Here, we
summarize the physiological role of EVs in various
body fluids and relate their presence with physiological
functions.
EVs in urine
The existence of lipid membranes in urine was first
described in the early 1990s (246). It was hypothesized
that these membranes were derived from intracellular
vesicles that were somehow released into the urine (247).
However, it was as recent as 2004 that urinary EVs were
first depicted as such (18) and it has now been estimated
that only about 3% of the total urinary protein content is
derived from EVs.
Cell type or body fluid/species Lipid analysis Observations Ref.
Urine/Homo sapiens LCMS EVs from urine samples of renal cell carcinoma patients and healthy
donors show a different lipid composition. First evidence of a
relationship between the lipid composition of urinary EVs and this
disease
(700)
TLC: thin-layer chromatography; LCFD: liquid chromatographyfluorescence detection; LCMS: liquid chromatographymass
spectrometry; GCFID: gas chromatographydetectorflame ionization detector; GCMS: gas chromatographymass spectrometry.
Fig. 3. Schematic of in vivo-derived EVs isolated from body fluids.
Cells from different human tissues of the body communicate through the secretion of EVs into proximal body fluids. EVs contain
proteins, lipids and RNA molecules that may affect the physiology of cells bathed in or lining these body fluids. Highlighted here are the
body fluids where EVs have been identified and their possible cellular origin. Pink spots represent body fluids, which are only present in
females. Green spots represent body fluids, which are only present in male. Yellow spots represent body fluids present in both female
and male. CSFcerebrospinal fluid; BALFbronchoalveolar lavage fluid.
Table II (Continued )
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An extensive description of urinary-derived EV content
has been reviewed elsewhere (248). The urinary EV cargo
suggests that cells along the renal epithelium, extending
from the glomerular podocytes (249,250) through the
proximal tubule, the thick ascending limb of Henle, the
distal convoluted tubule and the collecting duct, are
releasing EVs into urine (18,38). CD24, which is expressed
both by tubule cells and podocytes, has been proposed as a
suitable urinary EV marker (251). It is noteworthy that
urinary EVs may not only come from the kidney but also
from the ureters, the transitional epithelium of the urinary
bladder, the urethra (252254), and from the prostate
epithelial cells, especially when a prostate massage is
performed (255). Analysis of the RNA content from
urinary EVs showed that the majority of RNA within
EVs is rRNA, while only 5% of the total RNA aligned to
protein coding genes and splice sites. Exploration of these
coding genes revealed that the entire genitourinary system
might be mapped within EVs, which may play an emerging
role in cell regulation (167).
The role of urinary EVs as a reservoir of biomarkers and
as potential mediators of intrarenal signalling has been
suggested (256). Initially, it was thought that the main
physiological role of urinary EVs was the disposal of
senescent proteins and lipids from cells (257). Due to the
fact that excretion via EVs probably requires a significant
amount of energy, it has been proposed that EVs are
preserved through evolution, due to their impact in other
different physiological functions (258,259). It is possible
that EVs represent a mechanism for cell-to-cell signalling
along the nephron, through secretion and reuptake of
their content such as proteins, mRNAs and miRNAs that
can affect the function of the recipient cell (258). The
vasopressin-regulated water channel aquaporin-2 (AQP2),
an apical Na transporter protein, is predominantly ex-
creted via urinary EVs from renal collecting duct cells
(18,247,260). Thus, EVs apparently trigger AQP2 traffick-
ing towards the apical plasma membrane where they fuse,
thereby increasing water permeability across the nephron.
Other Na transporter proteins expressed along the renal
tubule, as well as their activators, were also detected in
urinary EVs (57,261263). Moreover, it has been specu-
lated that TammHorsfall protein (THP), an abundant
polymeric protein in normal urine, has a role on limiting
EVs fusion with cells in downstream nephron segments
(257). An additional role for EVs in kidney physio-
logy seems to be is through direct actions of EV-resident
proteins in the renal tubule lumen (257), such as the
angiotensin-converting enzyme (18,38), which could have
a role in the reninangiotensin system hence playing a role
in water (fluid) balance. Urinary EVs are described as
enriched in innate immune proteins, such as antimicrobial
proteins and peptides and bacterial and viral receptors.
This suggests a new role for urinary EVs as innate immune
effectors that contribute to host defence within the urinary
tract (264). Finally, it has been proposed that urinary EVs
exposing tissue factor (TF) could provide additional
sources of TF which could boost coagulation and hae-
mostasis, thus reducing blood loss and contributing to host
defence by reducing the risk of microorganisms entering
the body through urinary and urethral epithelia (265).
EVs in saliva
EVs from saliva contain proteins (56,266,267) and several
different RNA species (20,268271) which can be inter-
nalized by oral keratinocytes and macrophages (268,271)
and alter their protein expression. This suggests that
saliva-derived EVs are biologically active (268). As sali-
vary gland epithelial cells in culture release EVs and
epithelial cell markers can be detected on saliva-derived
EVs (56,272), it is likely that these cells are the source of
the EVs found in saliva (273). In addition to epithelial
cell markers, the granulocyte marker CD66b has also
been identified on saliva-derived EVs (272), suggesting
that saliva-derived EVs are mainly from epithelial cells and
granulocyte origin. Two types of EVs have been identified
in saliva, that is, 1 population that is heterogeneous in their
size (30250 nm), and 1 population that is homogeneous
in their size (2080 nm). The protein and RNA contents
of these 2 populations are dissimilar (266,269).
EVs isolated from saliva of healthy subjects have been
shown to contain TF and CD26. CD26 is a protein that
can cleave several different peptides, and saliva-derived
EVs have been shown to cleave substance P and chemo-
kines (60,266). TF may initiate blood coagulation and,
interestingly, saliva EVs induced clotting of vesicle-free
plasma (272). It has, therefore, been suggested that EVs
could be an important part of the process during which
humans and animals lick a bleeding wound to promote
coagulation and the subsequent wound healing.
EVs in synovial fluid
Improved flow cytometric assessment of EVs has revealed
that synovial fluid  a clear fluid secreted by membranes in
joint cavities, tendon sheaths and bursae  which func-
tions as a lubricant, has a distinct EV signature (274).
Synovial fluid-derived EVs have mainly been examined
in subjects with autoimmune diseases such as rheuma-
toid arthritis and juvenile idiopathic arthritis. Initial
studies on synovial EVs showed the accumulation and
distribution of citrullinated proteins via these specific EVs,
suggesting an important role in autoimmune mechanisms
since citrullinated peptides are specific autoantigens in
rheumatoid arthritis (275). Synovial fluid-derived EVs
have been observed, by immunoelectron microscopy, to be
associated with IgG and IgM immune complexes (275).
Moreover, they bear functional integrins, capable of
mediating anchorage to cell-surface adhesion molecules.
Therefore, they may represent a novel mode of deliver-
ing autoantigens at distances beyond that of direct cell-to-
cell contact (275). Furthermore, a mammalian nuclear
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DEK-phosphoprotein was observed in EVs from synovial
macrophages indicating the involvement of EVs in joint
inflammatory processes (276).
EVs in bile
Bile is a fluid that helps with digestion and the breaking
down of fats into fatty acids, which then can be taken up by
the cells in the digestive tract. Bile consists mainly of
cholesterol, bile acids and bilirubin. EVs were found in the
bile of bile duct ligated rats, suggesting the existence of
biliary EVs in vivo (277). Recently this was confirmed after
identifying EVs by their size, morphology and markers
such as CD63 and Tsg101 in this body fluid. Furthermore,
the same authors observed that biliary EVs were involved
in cholangiocyte regulatory mechanisms and proliferation
through interaction with primary cilia (278,279).
EVs in cerebrospinal fluid
Cerebrospinal fluid (CSF) has been described to have
many functions as an intermediary between blood and
brain for the transport of nutrients and growth factors,
and as a buffer for the brain to protect both the brain
tissue and the large vessels supplying brain circula-
tion. CSF is also involved in the elimination of toxins
and other metabolic by-products (280). Because of the
potential importance of EVs in the context of the CNS
and neurological diseases, the presence of EVs in human
CSF is of much interest. Numerous studies have demon-
strated the presence of EVs in CSF of humans (281,282)
that carry signalling and intracellular proteins (283). EVs
have been proposed to neutralize the synaptic-plasticity
disrupting activities of amyloid b-protein (Ab) in vivo,
primarily via the sequestration of Ab oligomers by
exosomal surface proteins, such as PrPC. These indicate
a protective role of EVs against Ab accumulation (284).
EVs in bronchoalveolar fluid
EVs in bronchoalveolar lavage fluid (BALF) are released
by cells residing in the lung and contain MHC class I and
II, CD54, CD63 and the co-stimulatory molecule CD86
(285). The presence of RNA and miRNA in those EVs
has also been documented (286).
So far, the main role described for EVs in BALF points
to immunity in the lung as a response to different stimuli
(287,288). BALF-derived EVs may act as signal conveyors
for nanoparticles (289), pathogens (290) and allergen-
induced systemic immune responses (291294). Upon
exposure to magnetic iron oxide nanoparticles, secretion
of EVs was shown to increase in a dose-dependent manner
in BALF of BALB/c mice, and the EVs were quickly
eliminated from alveoli into systemic circulation and
transferred their signals to the immune system, produ-
cing maturation of DCs and activation of splenic T cells
(289). Further supporting the role of EVs in the immune
response towards allergens and exogenous infections,
BALF EVs were shown to express the scavenger receptor
CD36, which has been implicated in bacterial recognition
(295). Moreover, EVs isolated from the BALF of mice
infected with M. bovis BCG had mycobacterial pathogen-
associated molecular patterns (PAMPs) and were immune
stimulatory (290).
EVs in nasal fluid
EVs have also been detected in the nasal secretions of
healthy humans. These vesicles were of the size of exosomes
and had surface markers considered to be enriched in
exosomes such as Tsg101, CD63, CD9 and CD81 (23).
Although, the functional significance of nasal EVs has to
be further investigated, they may, similarly to the EVs from
the lung, have immune modulatory effects. Within the field
of vaccine development, the intranasal distribution of EVs
for systemic delivery of drugs is under intense investigation
as theses vesicles could have therapeutic effects in the
brain, lungs and intestines (296298).
EVs in uterine fluid
EVs from the uterine fluid (also known as uterosomes) as
well as EVs from the oviductal luminal fluid (also known
as oviductosomes) have been described as a way of pro-
tein trafficking, which may play an important role in the
sperm capacitation and fertilization (299,300). Although
experimental data exist in murine models only, plasma
membrane calcium-transporting ATPase 4 (PMCA4)
protein  which is transported through EVs within the
uterine fluid during oestrus  is likely to be key to the
maintenance of Ca2 homeostasis and sperm viability
during their storage in the oviduct and during capacita-
tion and the acrosome reaction (299). Furthermore,
acquisition of sperm adhesion molecule (SPAM1)1 pro-
tein, localized outer surface of EVs, has been suggested to
be an important prerequisite for sperm maturation and
capacitation in the male and female reproductive tracts
(300).
In addition, EVs present in uterine fluid may directly
transfer information, such as miRNAs [hsa-miR200c,
hsa-miR17 and hsa-miR106a (301)] or proteins [CD52
(302) and leukaemia inhibitor factor (LIF) (303,304)]
contributing to the endometrial-embryo cross-talk essen-
tial for the embryo implantation process.
EVs in amniotic fluid
In 2007, EVs were detected in the amniotic fluid of
laboratory mice and 4 samples from women undergoing
routine amniocentesis (251). It has been speculated that the
origin source of the amniotic fluid-derived EVs could be
from both mother and foetus. The foetal kidney releases
EVs that contain specific markers, such as AQP2, CD24
and annexin-I, to the foetal urine; which is a major
constituent of amniotic fluid. A second fraction of EVs
expressing annexin-I and HSP70, but not CD24, might
originate from the maternal side (251). EVs from amniotic
fluid have been suggested to regulate the immune response
Marı´a Ya´n˜ez-Mo´ et al.
16
(page number not for citation purpose)
Citation: Journal of Extracellular Vesicles 2015, 4: 27066 - http://dx.doi.org/10.3402/jev.v4.27066
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ity
 of
 Sz
eg
ed
] a
t 1
0:0
2 0
7 N
ov
em
be
r 2
01
7 
in order to maximize foetal survival during pregnancy. In
this process, HSP72 was indicated as an important factor
(305), as it modulates intra-amniotic cytokine production
(306). Supporting an immune role of EVs, EVs from the
amniotic fluid were shown to be captured by human
monocytic THP-1 cells and to stimulate cytokine re-
lease and NFkB/STAT3 activation in a TLR-dependent
manner (307).
EVs in breast milk
Breast milk is a complex body fluid, rich in immunolo-
gical components that affect the development of the
infant’s immune system. It has been shown that human
breast milk contains EVs (271), but their origin is
uncertain. It has been established that breast milk EVs
differ from DC EVs, and it has been suggested that they
may originate from other cells present in breast milk,
from epithelial breast cells or even from other compart-
ments of the body that can reach breast milk through the
blood circulation (308). Interestingly, high expression
levels of immune-related miRNAs (such as miR-181a
and miR-17) in CD63 EVs were detected in human milk
during the first 6 months of lactation. Deep sequencing
technology has identified many miRNAs in human
breast milk EVs with an abundance of immune-related
miRNAs, suggesting that such EV miRNAs are trans-
ferred from the mother’s milk to the infant, possibly
having an essential role in the development of the infant
immune system (208). In fact, human breast milk EVs
have the potential to influence the immune system of the
infant at the protein level. Milk EV preparations have
been shown to inhibit anti-CD3 and anti-PHA-induced
(activated T cell) cytokine production and increase the
number of a specific group of T regulatory cells (308,309).
The isolation of EVs from breast milk and their
participation in the development and maturation of the
neonate’s immune system has also been described in other
species (207,310314).
EVs in blood
The first report of the existence of EVs in blood was almost
70 years ago and was later described as platelet ‘‘dust’’
(2,3). In addition, in the mid-1970s, vesicles of approxi-
mately 55 nm were identified in bovine, lamb and por-
cine serum (6,7). In the 1980s, the release of transferrin
receptor-containing EVs during the maturation of reticu-
locytes was demonstrated (12, 13). Since this early work on
blood-derived EVs, it has been recommended by some that
EV studies should preferably be conducted on plasma (46),
since plasma is the physiological fluid of blood and EVs
may potentially be generated in serum after the blood
collection during blood clotting (46,315,316). Conversely,
due to the many large proteins present in plasma, other
researchers have found EV isolation from serum to be more
reproducible (317).
Although plasma-derived EVs are a mixture of vesicles
from the cells lining the blood vessels and the different
cells found in blood, the largest individual population of
EVs in plasma is positive for platelet specific markers (such
as, CD41a, CD61 and GPIb) and are considered now to be
25% of the total blood EVs (318), in contrast to the
previous notion of 7080% (21,53,196,272,319,320). How-
ever, it has also been suggested that the platelet-marker-
positive EVs in plasma from healthy subjects are mostly
derived from megakaryocytes (321). As platelets are
induced to form EVs by different activatory mechanisms,
they may provide a versatile way for the platelet to
participate in various physiological maintenance functions
from haemostasis to immunity and development (43,322).
Finally, preparations of plasma-derived EVs may also
include cell organelles, such as mitochondria (323).
The protein and RNA content of plasma-derived EVs,
as well as the number of EVs present, has been shown to be
altered by several pathological states, suggesting that blood
can also harbor an EV population derived, for example,
from tumours (95,324). In addition, altered physiological
status (such as pregnancy) is reflected in the number and
origin of circulating EVs (309,325). The physiological func-
tions of plasma-derived EVs, such as in vascular biology,
coagulation and the maternalfoetal communication, will
be later described in more detail (see EVs in Vascular
Biology and EV functions related to pregnancy sections).
EVs in faeces
The existence of faeces’ EVs has been described (326).
Faeces contain bacterial EVs, which seem to have both
local and systemic pro-inflammatory effects. The group
of Dr. Yong Song Gho presented in the last (ISEV 2014)
meeting (327) the physiological role of faeces EVs by
using a murine model. Peritoneally injected faecal EVs
were reported to induce a dose-dependent peritoneal and
systemic inflammation in the mice. In addition, EV
uptake by macrophages induced a significant release of
TNF-a and IL-6. These results are in accordance with
other studies demonstrating that EVs derived from gram-
negative intestinal Escherichia coli (E. coli) induce
vascular inflammation in vivo (328). This suggests that
EVs from the gut microbiota may have the capacity to
induce systemic inflammatory responses. More studies
are needed to further demonstrate the physiological role
of faecal EVs. The role of bacteria-derived EVs will be
discussed in more detail in the Bacterial EVs section.
EVs in seminal plasma
Mammalian seminal plasma contains multiple types
of EVs that originate from the epididymal duct and the
male accessory glands (329331). Interestingly, seminal
plasma was one of the first biofluids in which EVs were
characterized (9). These EVs were first termed prosta-
somes since they were thought to be a specific product
from the prostate (8). However, it is now known that
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seminal plasma EVs originate from distinct sources within
the male reproductive tract and, therefore, even if the
prostate is the major contributor to seminal plasma EVs,
the term prostasome should not be used to refer to all EVs
found in seminal plasma. Similarly to EVs in other body
fluids, seminal plasma EVs contain a characteristic sets of
proteins, lipids and RNA molecules (22,228,229,332,333),
but there also exist differences in the composition of the
EVs released by the different organs of the male repro-
ductive tract. For example, prostasomes, which have been
characterized by comprehensive proteomic approaches
(22,332), contain prostate specific proteins such as pro-
static acid phosphatase, prostate specific antigen or pros-
tate stem cell antigen. Moreover, different types of EVs
may be released by the same organ. It has been shown that
seminal plasma from vasectomized men contains at least
2 different subgroups of EVs that have prostate specific
markers (334), but that differ in size, density and lipid and
protein content (335). It is also noteworthy that the EV
composition of seminal plasma of different mammals is
likely different, as the presence and functions of the
accessory sex glands vary between species. For physiolo-
gical functions of seminal plasma EVs, see EVs in male
reproduction section.
EVs in vascular biology
Coagulation
So far, one of the best characterized physiological roles of
EVs is their capacity to enhance coagulation and thus
participate in haemostasis (Fig. 4). Further, the procoa-
gulant capacity of EVs seems to be amplified in several
pathological processes, for example, in EVs generated by
cancer cells (11). Since the first descriptions of a pro-
coagulant factor in plasma (2,3), speculation about the
significance of EVs during the various spatio-temporal
phases of coagulation has been ongoing [reviewed in
more detail in Ref. (336)]. The physiological relevance of
EVs in coagulation is supported by clinical disorders in
which microvesiculation is impaired resulting in blee-
ding tendency (337339); the most studied of which is
Scott syndrome, a severe bleeding disorder with a reduced
procoagulant effect of platelets (339). In this disorder, an
impaired phospholipid scramblase activity has been
demonstrated, leading to reduced PS exposure, decreased
release of procoagulant vesicles and low prothrombinase
activity (340). Recently, a defect in the gene enco-
ding TMEM16F, a Ca2-gated ion channel and a
Ca2-dependent phospholipid scramblase, was identified
for Scott syndrome (341), helping to explain the relation-
ship of lipid bilayer changes with the vesicle formation.
The physiologically relevant procoagulant role of EVs is
supported by a study of sedentary men in which increased
formation of procoagulant platelet-derived EVs during
hypoxic exercise training enhanced in vitro thrombin
generation (342). Furthermore, the addition of exogenous
platelet EVs to a flow model of circulation induced
thrombosis (343). The procoagulant activity of EVs
seems to be predominantly exerted by the larger-sized
EV populations from different cellular sources rather
than exosomes (53,102), but contrasting evidence has
been presented particularly in regard of the TF EVs
(344), and as reviewed in Ref. (345). Most importantly,
procoagulant EVs were also reported to be functional in
other body fluids such as in saliva and urine of healthy
subjects (265,272).
Assigning a defined procoagulant role for EVs in
physiology is not only complicated by the lack of studies
addressing normal physiological status of healthy humans,
but also by the presence of EVs from several cellular
sources (particularly in blood) and the spatio-temporal
complexity of the coagulation process itself. Cellular
Fig. 4. EVs in coagulation.
Haemostasis: Originating from various sources (monocytes,
endothelial cells, platelets), procoagulant (tissue factor (TF)-
EVs and phosphatidylserine (PS)-bearing EVs) and anticoagu-
lant, as well as pro-fibrinolytic EVs may circulate at low levels in
normal, healthy blood, contributing to the maintenance of the
homeostatic balance in blood coagulation. Up-regulated coagu-
lation or thrombosis: Various clinical conditions (cancer, cardi-
ovascular diseases, inflammation, diabetes, sepsis and others) may
trigger the coagulation system, activating circulating monocytes
and platelets, making endothelial cells procoagulant and resulting
in increased generation of procoagulant EVs, particularly TF
EVs, thus leading to a hypercoagulable condition with thrombotic
events, hallmarked with fibrin formation and platelet entrapment
(thrombus formation).
Marı´a Ya´n˜ez-Mo´ et al.
18
(page number not for citation purpose)
Citation: Journal of Extracellular Vesicles 2015, 4: 27066 - http://dx.doi.org/10.3402/jev.v4.27066
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ity
 of
 Sz
eg
ed
] a
t 1
0:0
2 0
7 N
ov
em
be
r 2
01
7 
interactions and cooperation of EV populations from
several cellular sources are likely occurring under the
various phases of coagulation (346) (Fig. 4). This hampers
the analysis of the cellular origin of the procoagulant EVs.
In addition to platelets, various leukocyte populations [for
review, see (336)], red cells (347), ECs (336) and even
megakaryocytes (321) may participate in forming procoa-
gulant EVs. Moreover, the so-called ‘‘haemostatic ring,’’
that is, smooth muscle cells (336,348) may act as a source of
procoagulant EVs. Activated monocytes (336,349,350)
shed TF EVs (351,352) and neutrophils may also con-
tribute (353). The presence or absence of TF in EVs can be
regarded as the major determinant of the procoagulant
potential of an EV-population (336).
EV-mediated transfer of TF in circulation may also be
relevant. Monocyte-derived TF EVs were reported to
bind activated P-selectin-expressing platelets via PSGL-1
and to fuse with them, leading to enhanced TF-FVIIa
activity (236). A similar transfer of TF may also operate
with other cells within the circulation and, in addition,
uptake of heterogenic EVs may promote TF expression by
other cells as, for example, neutrophil-derived EVs were
reported to induce TF expression by ECs (354). While a
low concentration of TF EVs may play a role in nor-
mal haemostasis and clot formation, to what extent this
notion holds true in small vesselsas opposed to large
vesselsremains unclear (336). Increased circulating levels
of procoagulant, particularly TF EVs, have also been
associated with pathological states. In diseases such as
cancer (355,356) or acute coronary heart syndrome (357),
the thromboembolic risk mediated by EVs may be en-
hanced. Altered coagulation states have also been ob-
served under normal physiological conditions. This may
include a transient hypercoagulable state during a healthy
pregnancy, whereas pre-eclampsia is characterized by an
increased thrombotic tendency which may depend on the
increased levels of TF-expressing placenta-derived EVs in
the circulation (358360).
The exact role of EVs in the balance between coagula-
tion and anticoagulation remains unclear, as the pre-
dominantly procoagulant role of EVs has been challenged
by observations that EVs may also harbour anticoagulant
and fibrinolytic properties. ECs, as well as monocytes,
express tissue factor pathway inhibitor (TFPI) (361). TFPI
inhibits the TF-Factor VIIa complex in a Factor Xa-
dependent manner, in addition to inhibiting Factor Xa
(361). TF EVs and TFPI EVs have been detected in
normal pregnancies, but their presence was found to be
increased in gestational vascular complications (362).
Furthermore, platelet activation and the released EVs
also induced Factor Va inactivation by activated protein C
and TFPI expression (363). This supports the hypothesis
that EV sub-populations may have different pro- or
anticoagulant properties (53). The role of EVs during the
different phases of haemostasis and coagulation may
depend on both the quality and the quantity of circulating
EVs. An inverse correlation between the EV number and
their capacity to form both thrombin and thrombin
antithrombin complexes in plasma in healthy individuals
has been shown (364). This may suggest that EVs mainly
execute an anticoagulant role, as the low amount of
thrombin induced by EVs activates protein C that, in
turn, inactivates Factor Va (364). Finally, fibrinolytic
activity may also be another physiological counterpart of
the procoagulant effect of EVs in circulation, as EVs may
generate and disseminate plasmin activity due to plasmi-
nogen activators carried by EVs from ECs and leukocytes,
but not by EVs of platelet or erythrocyte origin (365).
In summary, cell-derived EVs from multiple sources,
with various procoagulant, anticoagulant and fibrinolytic
properties, are physiological constituents of the blood and
other body fluids in healthy individuals. At the moment,
the highly variable normal circulating concentrations and
compositions of EVs reported in the literature [for review
(366,367)] hamper data interpretation. Therefore, defined
standards, protocols for pre-analytical sample prepara-
tion, as well as optimized EV analyses, are required before
a complete understanding of EV function in coagulation
and fibrinolysis can be reached.
Reticulocyte maturation
Exosomes, in their strict sense, were originally termed and
described in reticulocytes where they allow remodelling of
the plasma membrane in the maturation to erythrocytes
(13,368). Reticulocytes are immature erythroid cells gen-
erated through enucleation of precursors in the bone
marrow. Remarkably, during their maturation to erythro-
cytes, reticulocytes selectively remove proteins, noticeably
the transferrin receptor, as well as membrane-associated
enzymes, through the formation of reticulocyte-derived
exosomes, rex (14,369). Studies of rex have revealed that
segregation of proteins into endosomal membranes occurs
via different routes involving endosomal sorting complex,
lipid rafts and lectin clustering (370). Of particular interest
is the secretion of rex through a non-classical secretion
mechanism involving the tumour suppressor-activated
pathway 6 (TSAP6) (371). Thus, functional studies with
TSAP6 KO mice demonstrated delayed reticulocyte ma-
turation and retention of transferrin receptor leading to
microcytic anaemia, strongly indicating possible links of
red blood cell disorders and rex secretion. In addition, an
increasing number of studies have identified proteins with
other relevant biological activities found in these EVs
(372). For instance, it has now been established that rex
contain a4b1 integrin, suggesting that removal of this
adhesion molecule from mature erythrocytes likely avoids
pathological processes due to aberrant cyto-adherence
(373). Similarly, they have been shown to contain AQP1,
indicating that extracellular osmotic conditions can induce
release of this protein and suggesting a role for its release
Biological properties of EVs and their physiological functions
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during the maturation of erythrocytes (374). In addition,
galectin-5 is also partially sorted out in rex, likely con-
tributing to the clearing of specific glycoproteins from the
reticulocyte membrane (62). The first proteomics analysis
of rex isolated by ultracentrifugation from rat reticulocytes
identified close to 1,000 proteins revealing canonical
exosomal proteins, but also missing rex-protein markers
identified by other biochemical analyses (375). Altogether,
these data clearly indicate that reticulocyte-derived EVs
are a selective cargo-disposal pathway for destruction of
obsolete proteins in the differentiation of reticulocytes into
erythrocytes. Yet, rex were also shown to be involved in
induction of reticulocitemia, antigen presentation and
modulation of immune responses (376). Clearly, further
studies on rex might reveal critical insights into erythro-
poiesis and into novel therapeutics for red blood cell
diseases.
Function related to the vascular biology
Leukocyte- and platelet-derived EVs are believed to be
responsible for the delivery of pro-angiogenic factors at
sites of angiogenic sprouts (377). EVs derived from
mononuclear blood cells are reportedly involved in hor-
izontal mRNA transfer and induce pro-angiogenic effects
in vitro and in vivo (186). These results are complemented
by a study where human EC network formation was im-
proved by supernatants derived from T cells and mono-
cytes co-cultured under pro-angiogenic conditions (378).
EC stress influenced the protein and RNA content of EC-
derived EV, which would interact with macrophages in
vascular niches to promote vascular growth (379,380).
Endothelial as well as tumour cells secrete delta-like 4
(Dll4). The blockade of Dll4 inhibited tumour growth by
inducing a form of non-productive angiogenesis, poor
perfusion and hypoxia (381). EV-associated Dll4 did not
require direct cell contact to alter Notch signalling and
may thus promote the transformation of ECs into tip cells,
angiogenic sprouting and increased vessel density (382).
Moreover, EVs derived from mesenchymal stem cells
(MSC), incubated under varying oxygen tensions, in-
creased EC migration and proliferation in vitro and regu-
lated vascular adaptation to hypoxia in vivo (383).
Hypoxia-cued EVs from multiple myeloma cells were
identified to accelerate angiogenesis by targeting the
FIH-1/HIF-1 signalling pathway via miR-135b (384).
Current research activities focus on extracellular miRNAs,
vesicular transport of angiogenesis-associated miRNAs
and signalling networks to generate a more detailed
understanding of spatio-temporal interactions and reg-
ulatory signalling cascades in vascular homeostasis
(380,385387). In this regard, EV-mediated protection
against endothelial apoptosis depended on annexin-I/PS
receptor function in target ECs and the transfer of
miRNA-126 promoted endothelial repair (388,389). EV-
mediated cross-talk between ECs depends on miR-214 and
was shown to activate an angiogenic programme in target
cells, while EC senescence was suppressed (390). Increased
understanding of the role of EVs in vascularization has
opened up the potential use of EVs in therapeutics, with
emerging concepts focused on the development of EVs
for pro- or anti-angiogenic therapies used for organ
regeneration or cancer treatments, respectively.
EV in the immune system
Innate immunity
The innate immune system is the first mechanism of
vertebrate defense against pathogen infection. EVs act
on the innate immune system as paracrine messengers and
have been mainly described as pro-inflammatory media-
tors (Fig. 5) inducing or propagating inflammatory signals
during infections (391,392), sepsis (393,394), chronic
inflammatory diseases, such as RA (395,396), athero-
sclerosis (397), type 2 diabetes (398) and pre-eclampsia
(399). In patients with autoimmune diseases (400403) or
with renal (404) and vascular (405) diseases, increased
levels of EVs carrying complement components were
detected and associated with complement activation.
However, a strong anti-inflammatory therapy suppressed
inflammation in patients with RA but not the number of
EVs associated with complement activation, suggesting
that inflammation may not be the main underlying cause of
EV release (403).
In addition to promoting inflammation, EVs released
by innate immune cells can also contribute to negative
regulation of inflammation (Fig. 5), for example, by
inducing TGFb secretion or by regulating endogenous
pro-resolving lipid mediators (406).
Various cell types of the innate immune system have
been shown to release EVs (seeInnate immunity section).
The cargo of these EVs and the type of recipient cell
determine their functional effects. EV components that
were demonstrated to affect the innate immune response
include agonists of pattern recognition receptors (e.g. the
TLRs), endogenous pro-inflammatory ligands such as
high-mobility group box 1 protein [HMGB1 (407)],
membrane phospholipids (408), miRNAs (409), DNA
(410), fibronectin (411) and several PAMPs, including
lipoarabinomannan and glycopeptidolipids (290,412,413).
In addition, cytokines found to be associated with EVs
included IL-1b (391,395,414), IL-1a (141), TNFa (415),
TGFb (416). Furthermore, it has been demonstrated that
EVs present in urine contain viral receptors and anti-
microbial proteins and peptides that could inhibit the
growth of pathogenic and commensal E. coli and induce
bacterial lysis (264).
These data indicate that the role of EVs in innate
immunity is complex and that the role of systemically
released EVs is unclear. However, several studies have
addressed the composition and function of EV isolated
from in vitro from cultured innate immune cells.
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Monocytes/macrophages. EVs released from monocytes/
macrophages can exert several different functions. First,
these EV were shown to cause inflammation-induced
programmed cell death in vascular smooth muscle cells
via transfer of functional pyroptotic caspase-1 (417).
Subsequently, it was shown that macrophage-derived EVs
could induce differentiation of naı¨ve monocyte recipient
cells to macrophages (206). The macrophage-derived
vesicles contained high levels of the miRNA molecule
miR-223, which is an important regulator of myeloid cell
proliferation and differentiation. In addition, EVs re-
leased by macrophages contain MHC class II and co-
stimulatory molecules and, similar to DC-derived EVs,
can play a role in antigen presentation (418,419). Never-
theless, most studies focused on the function of EV
released by microbially infected macrophages.
Microbial infection of macrophages (290,413,416) was
shown to modify their EV contents and to promote the
release of EVs that stimulate pro-inflammatory responses
in resting macrophages (412,413). EV released from
macrophages infected with Mycobacterium tuberculosis
were shown to contain mycobacterial products, including
cell wall components such as the glycolipid virulence
factor lipoarabinomannan (420). Upon co-incubation
with DC, these EV were able to induce antigen-specific
T cell proliferation and may, therefore, be regarded as
amplifiers of the immune response in situations where the
initial number of bacteria is still low. Macrophages treated
in vitro with EVs from Mycobacterium-tuberculosis-
infected cells secreted pro-inflammatory cytokines and
chemokines, which could subsequently lead to disruption
of the integrity of respiratory epithelial cell monolayers
(420,421). These pro-inflammatory cytokines and chemo-
kines could stimulate migration of other immune cells to
the site of infection in vivo (420). In addition to bac-
terial pathogens, macrophages that are infected with the
immune-modulatory Leishmania parasite were shown to
secrete EVs containing the immune-modulatory Leishma-
nia surface protein GP63 (422). These EVs may deliver
immune down-modulating signals to bystander macro-
phages to evade immune attack. Other immune down-
modulatory effects of macrophage-derived EV include the
inhibition of complement activation and induction of
TGFb release (416).
Fig. 5. Physiological role of EVs related to cells of the innate immune system.
Activated macrophages release EVs that contain cytokines, miR-223 and carry out lateral transfer of receptors influencing myeloid
cell proliferation and differentiation. Neutrophilic granulocytes (PMN) produce different types of EVs, depending on the type of
stimulus. Neutrophil-derived EVs counteract the activation of immune cells or inhibit bacterial growth directly. EVs containing HSP-70
activate NK cells to combat tumour cells. DCdendritic cell; NKnatural killer; NKG2Dnatural killer group 2D; HSPheat
shock protein.
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PMN. Polymorphonuclear neutrophils (PMN) represent
the most abundant cell type involved in innate immunity.
These have been shown to generate large EVs, termed
ectosomes, at the plasma membrane. Both the composi-
tion and the biological properties of these EVs depended
on the type of stimulation that the producing cells
undergo (423,424).
PMN-derived EVs induced the secretion of the anti-
inflammatory cytokine TGFb from monocytes or DCs
and decreased the release of the inflammatory cytokines
IL-8, IL-6 and TNFa (406,425). They also promoted
the phagocytosis of apoptotic PMN and the release of
pro-resolving mediators from macrophages (424). The
anti-inflammatory protein annexin A1 from PMN-EVs
impaired the adhesion of leukocytes to ECs (426), while
EVs produced during the process of PMN extravasation
seemed to enhance the endothelial barrier function (427).
PMN-EVs may also display a pro-thrombotic function by
the encapsulation of platelet-activating factor, combined
with the exposure of activated Mac-1 (CD11c/CD18)
integrin (428,429) and TF (353).
Similarly to the macrophage-derived EVs, a special
type of PMN-derived EVs could mediate direct anti-
bacterial effects, which were selective to specific bacterial
strains (423). The anti-microbial effect of these neutrophil-
derived microvesicles was of a bacteriostatic, rather than
bactericidal, nature and is thereby different from the
action of neutrophil extracellular traps (NETs) (430).
Instead, bacterial growth was inhibited by formation of
large aggregates between bacteria and EVs which relied
on continuous remodelling of the actin cytoskeleton and
on the exposition of Mac-1 integrin.
NK cells. As important cells of the innate immune system,
NK cells keep the homeostatic balance, combat viral
invasion and prevent survival or spreading of malignantly
transformed cells. NK cells have generally been consid-
ered as components of the first early innate immune
defense line, as they do not require ‘‘priming,’’ that is,
previous contact with the invading organisms. The old
idea that NK cells would kill any target lacking self
MHC class I molecules (the ‘‘missing self’’ hypothesis)
has been reconsidered in the past decade (431). It is now
clear that NK cells have multiple inhibitory receptors that
recognize self-MHC class I (e.g. killing inhibitory recep-
tors) and activating receptors (e.g. NKG2D) (432). The
balance between activating and inhibitory signals deter-
mines whether or not NK cells become activated.
NK cells could be activated by HSP0 present as soluble
or membrane-bound protein in EVs (433). Release
of HSP70-containing EVs by tumour cells activated NK
cells, which, via recognition of stress-inducible NKG2D
ligands on tumour cells, can reduce tumour growth
(434,435). Furthermore, EV-associated Bcl2-associated
gene 6 (BAG-6), which is required for the protein
stabilization and accumulation of HSP70 upon heat
shock, can activate NK cells (436).
On the other hand, NK cell function can be down-
regulated by EVs containing the NKG2D ligands MICA/B
(MHC class I-related chains [MIC] A/B (127,437,438).
Treatment of NK cells with EVs containing MICA*008
not only downregulated NKG2D expression, but also pro-
voked a marked reduction in NK cytotoxicity independent
of NKG2D ligand expression by the target cells (439), thus
providing a mechanism for tumour immune escape.
Finally, human NK cells themselves constitutively
release EVs. Although the release of EVs by NK cells
may be independent of their activation status (134,440),
the composition of these EVs can change depending on
the environmental factors. NK cell-derived EVs exhibited
cytotoxic activity against tumour cells and activated
immune cells (134,440). Taken together, both NK cell-
derived EVs and stimulation of NK cells by EVs released
by stressed cells or tumour cells can play a role in immune
regulation.
Besides the above-described roles of innate immune cell-
derived EV in regulation of inflammatory processes, EVs
have also been implicated in resolution of inflammation,
which is important for the maintenance of tissue home-
ostasis. Resolution is a biochemically active process that
involves the local and temporal biosynthesis of pro-
resolving lipid mediators or anti-inflammatory proteins,
for which EVs were identified as important regulators
(424,441). Self-limited acute inflammation temporally
generated leukocyte-derived EVs with pro-resolving lipid
mediators in vivo (441). In this context, EVs enriched in
resolvin D1 or lipoxin A4 analogues were shown to protect
against inflammation in the temporomandibular articular
joint (441).
Mast cell-derived EVs. Mast cells are highly versatile
cells strategically located at tissues facing the environ-
ment, but also in spleen and lymph nodes. Besides their
role in IgE-mediated allergic reactions, mast cells con-
tribute by secreting a plethora of immune-modulatory
mediators to innate immunity, chronic inflammation
and regulation of adaptive immunity (442). Although
much is known about the secretion of soluble media-
tors from secretory granule stores via IgE cross-linking,
the release and physiological role of mast cell-derived
EVs in immune modulation is rather obscure (443). Mast
cell-derived EVs have been reported to contain immune-
modulatory proteins, for example, MHC II, LFA-1,
ICAM-1, HSPs and the high-affinity IgE receptor
(444,445), and were able to target other mast cells; induce
DC maturation and deliver antigens for cross-presenta-
tion; and induce B- and T-cell activation (16,445). Al-
though the molecular mechanisms behind these processes
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are largely unknown, the finding that mast cell-derived
EVs could functionally transfer RNAs to recipient cells
was of great importance (16).
Acquired immunity
Capture of EVs by APCs: modulating the immune
response. Antigen-presenting cells, such as DCs, macro-
phages and B cells, are key players in the translation of
information from innate to adaptative immune responses
through the capture and processing of antigens and
presentation of these antigens using MHC molecules,
together with co-stimulatory signals (Fig. 6).
EVs released by any cell type can function as a source of
antigens for APCs. EVs released by a given tissue can
harbour antigens signalling the presence of infection/
inflammation or malfunctioning of that given organ or
tissue. Consequently, such EVs can induce immunogenic
or tolerogenic responses as necessary. Several studies
addressed the requirements of EV capture by APCs.
Integrins and adhesion molecules on EVs and their lipid
Fig. 6. EVs in the immune system: antigen presentation and acquired immunity.
EVs may have a role in both the origin and progress of the acquired immune response, acting at different levels and on different cells.
This figure summarizes how EVs are involved in this process. APCantigen-presenting cell; Tregregulatory T cell; NKnatural
killer; MHCmajor histocompatibility complex.
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content may facilitate their attachment and fusion with the
plasma membrane of ‘‘acceptor’’ cells. In DCs, internali-
zation of EVs was shown to be an active process (inhibited
by cytochalasin D, EDTA or low temperatures, among
others) and involved the action of integrins (CD51, CD61,
CD11a), CD54, PS and MFGE8 (96). Recently, the
participation of sugar domains in EV capture has also
been proposed. The capture of Jurkat cell-derived EVs by
mature DCs (mDCs) was almost completely inhibited by
blocking Siglec-1, a sugar-binding lectin (446). Consistent
with this observation, mouse plasmacytoid DCs (which
express Siglec-H) were able to capture EVs in vivo (447).
Other sugar-binding proteins involved in capture of APC-
derived EV include sialoadhesin (CD169) on lymph
node macrophages that binds to a2,3-linked sialic acids
on the surface of B cell-derived EVs (54) and galectin-5,
a b-galactoside-binding lectin on macrophages, which
participates in the capture of erythrocyte-EVs (62).
EVs captured by APCs can both convey stimulatory or
down-regulatory signals to these cells and contribute to
antigen presentation. Although initial studies indicated
that internalization of blood-borne allogeneic EVs by
splenic DCs did not affect DC maturation (96), other
reports have shown that the cellular source and molecular
composition of EVs determine how the EV affect the
function of immune cells (448).
Several lines of evidence indicate that antigens carried
to APCs via EVs can be used to activate antigen-specific
T cell responses. Circulating EVs transporting alloanti-
gens, for example, activated anti-donor CD4 T cells
after being captured by splenic DCs (449). Furthermore,
EVs from intestinal epithelium bearing exogenous pep-
tides in MHC II interacted preferentially with DCs,
potentiating peptide presentation to T cells (450). In the
context of microbial infections, EVs derived from
Toxoplasma gondii were transported to the spleen, where
these EVs elicited a systemic and protective Th1 immune
response (451). Furthermore, EVs released by ECs
infected with cytomegalovirus could carry virus-derived
antigens to DCs, which, in turn, activated specific CD4
T cells (452). Antigen delivery via EV released by tumour
cells could either potentiate the anti-tumour immune
response or inhibit this response, for example, by pre-
venting T cell or DC activation (44,453,454).
Release of EVs by APCs: another way to present
antigens. Besides presentation of EV-associated antigens
acquired from non-immune cells, APCs themselves also
release EVs containing peptide-MHC I or II complexes
and co-stimulatory molecules, which can contribute to
antigen presentation (15,455,456). APCs release EVs in a
constitutive manner, but this secretion seems to be
increased after stimulation, such as following TLR
ligation on DCs (457) or BCR cross-linking in B cells
(458). Maturation of APCs can lead to increased levels of
co-stimulatory molecules on the released EVs (459,460).
EVs secreted by DCs and B cells could stimulate pri-
med CD4 T cells or cognate T cell clones. In contrast,
APC-EV-mediated stimulation of naive CD4 T cells
required bystander mDC or B cells (285,461,462). Besides
carrying MHC-peptide complexes, B cell-derived EVs
were shown to carry a whole antigen, which was bound to
EVs via surface Ig (462). Several lines of evidence have
indicated that mDC-derived EVs are able to elicit potent
immune responses, whilst immature DC-derived EVs
promote tolerance. Examples of immune-activating ef-
fects of mDC-derived EVs include the induction of T-cell
proliferation and anti-microbial responses by EVs bear-
ing pathogen-peptide-MHC-II complexes derived from
bacterially infected DCs (463,464) and induction of T cell
proliferation and secretion of IL-5 and IL-13 by B-cell
EVs loaded with a birch allergen (465). On the other
hand, EVs released by CD95L- or IL-10- expressing
immature DCs have been associated with tolerogenic
effects, such as the promotion of graft survival (466) and
reduction of the inflammatory response in a model of
arthritis (467,468).
T cell-derived EVs. EVs released by T cells can be targeted
to many different cell types thereby inducing a wide variety
of immune regulatory effects ranging from immune
activation to immune suppression (469). Although T cells
release EVs constitutively, TCR triggering and intracellu-
lar calcium stimulation increased EV secretion (470).
Activated T cells can produce immune-regulatory EVs
that carry MHC, TCR, APO2 ligand, FasL (471) and
NKG2D ligands and, for example, inhibit NK cytotoxicity
(472), block T cell stimulation (473), promote T cells
apoptosis (474) and down-modulate the T cell stimulatory
capacity of antigen-presenting cells (475); thereby con-
tributing to dampen immune responses. Furthermore, T
regulatory cells produced EVs expressing CD73 that
contributed to their suppressive role (476) and prolonged
allograft survival in a model of kidney transplanta-
tion (477). Besides these immune suppressive effects, T
cell-derived EVs were implicated in RANTES (CCL5)-
dependent induction of T cell proliferation (478) and in
the promotion of immunogenicity via gene regulation in
targeted APCs (164). Furthermore, T cell-derived EVs
could activate mast cells resulting in degranulation, IL8
and IL24 induction (479,480).
Although EVs can be transferred between cells at a
distance, the lytic synapse between CD8 cytotoxic T cells
and infected target cells or tumour cells (481), as well as the
immune synapse between T cells and antigen-presenting
cells (201), provides a specialized platform for the efficient
transfer of EVs. During the formation of these synapses,
intercellular compartments containing vesicles move
Marı´a Ya´n˜ez-Mo´ et al.
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towards the target cells in order to confine EV release
towards the synaptic cleft.
MSC-EVs. After the description of the multi-lineage
potential of human mesenchymal stem/stromal cells
(482), MSCs have emerged as one of the most intensively
studied adult stem cell population so far (483). Compelling
evidence indicates that in addition to their multipotent
capabilities, MSCs can modulate both innate and adaptive
immune responses and their therapeutic use in many
immunologically related diseases have been promising
(370,484,485). Although some pre-clinical in vivo studies
implied that MSCs home into various tissues, especially
into sites of injury and inflammation or into tumours,
(486489), other studies suggest that migration of MSCs
into damaged tissues may not be required for MSCs to
exert their therapeutic functions. According to novel
findings, MSCs mediate their clinical effects in a paracrine
manner rather than by cellular interactions (490492). In
this context, part of this paracrine/endocrine mechanism
of MSCs is thought to be mediated by the MSC-derived
EVs (493) (Fig. 7). MSC-derived EVs have been shown to
mediate immune suppressive effects, enforce M2 macro-
phage polarization and drive Treg cell induction (494).
Furthermore, it was demonstrated that MSC-EVs sup-
pressed T-cell proliferation and enhanced the proliferation
of the regulatory CD4CD25FOXP3 T-cell popula-
tion in vitro upon co-culturing with PBMCs (495497).
Strikingly, in an individual treatment attempt of a steroid-
resistant grade IV graft-versus-host disease patient, MSC-
EVs suppressed the symptoms over time without revealing
any side effects; similarly to that previously reported for
MSC administration (495,498,499). Additional examples
in which MSC-EVs modulated immune responses in a
similar manner to MSCs have come from studies using a
murine model of kidney ischaemia and reperfusion (I/R)
injury (188,195,500502). Here, MSCs as well as their EVs
were found to protect I/R kidneys by promoting epithelial
cell survival (503505), most likely during the early phase
rather than in the late phase of kidney I/R injury (496).
Studies in I/R kidney, as well as in affected cardiac and
lung tissues, point towards innate immune system regulat-
ing activities of MSC-EVs rather than Treg cell-dependent
mechanisms (493,496,506). In summary, although the
exact mode of action needs to be unravelled, evidence
suggests that MSC may mediate their beneficial therapeu-
tic impact by means of MSC-EVs. As non-replicating units
that can be sterilized by filtration, MSC-EVs provide
several mayor advantages for the clinical application
compared to MSCs. This enhances the relevance of
MSC-EVs qualifies them as a very promising tool for
future regenerative and immune modulating therapies.
EV functions related to pregnancy
Successful pregnancy relies on the immunological com-
munication between the foetus and the mother. Direct cell
cell interactions, EVs and soluble mediators are all
involved in these communication pathways, both at the
fetomaternal interface and/or at a systemic level (507,508)
(Fig. 8). The presence of trophoblast cells in maternal
blood was shown in the early 1990s (509) and, subse-
quently, circulating trophoblast-derived membrane parti-
cles [syncytiotrophoblast (STB) microvillous membranes;
Fig. 7. EVs from mesenchymal stem cells (MSC).
EVs derived from MSCs can induce different effects depending on the target cell, as summarized here. DCdendritic cell; NK
natural killer.
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STB microvillous membrane fragments; placental debris]
were reported in plasma of pregnant women (510,511).
STB-derived vesicles, both MVB-derived exosomes and
syncytial membrane-released microvesicles/microparticles
(STBMs), are simultaneously present in the maternal
blood throughout pregnancy and influence the maternal
immune system. The role of EVs and their relationship
with pregnancy complications have been investigated by
several research groups (309,325,512,513). Both the phe-
notypic composition and number of circulating EVs were
reported to be altered in the plasma of pregnant women
compared to non-pregnant healthy individuals (514516).
Increased amounts of circulating CD14 (monocyte-
derived) EVs and reduced numbers of CD41/CD42
(platelet-derived) EVs were detected during pregnancy. In
contrast, there was no difference in the number of T- and B
cell-derived EVs (517).
As previously outlined, EVs found in uterine fluid have
been associated with sperm capacitation, fertilization
(299,300) and with embryo implantation (301304). EVs
have been shown to play an immune regulatory role
whereby they may protect the semi-allogenic foetus. The
production of different types of vesicles by STBs is limi-
ted by maternal conditions. On the other hand, while
STBM were found to be immunoactivating, procoagulant
and anti-angiogenic, exosomes had immunosuppressive
properties (512). STBM may interact with neighbouring
cells including lymphocytes, monocytes, neutrophils, pla-
telets and ECs exerting a wide range of effects. STBM
bound to circulating peripheral T lymphocytes inducing
STAT3 phosphorylation in Tcells (517,518). Furthermore,
STBM affected local cytokine production and regulated
cytokine responsiveness of neighbouring immune cells.
They modified the IL-6 sensitivity of CD4 lymphocytes
by the downregulation of their IL-6Ra expression, which
may be important in the development and maintenance of
local immune tolerance (519). EVs were reported to induce
pro-inflammatory response via their danger molecules
including HMGB1 and HSP-70 (512,520,521), and to
mediate procoagulant activity by their surface expression
of TF. Their Flt-1 and endoglin contents contributed to
endothelial dysfunction (522). In contrast, STB-derived
exosomes induced apoptosis in T lymphocytes through the
downregulation CD3-zeta chain expression (518) and
downregulated cytotoxic activity by inducing apoptosis
via FasL/TRAIL (523) or by inhibiting the NK cell
cytotoxic activity via NKG2D receptorligand interaction
(524). Secretion of other immunomodulatory molecules,
such as PD-L1/B7-H1/CD274 on exosomes has also been
reported (525). Thus, these EVs may have a role in the
maintenance of successful pregnancy through downregu-
lation of T cell activity (309). STBM production seems to
Fig. 8. Summary of functions of EVs released by syncytiotrophoblasts.
Syncytiotrophoblasts and EVs secreted by them (STMBs) control both maternal adaptive and innate immunity during pregnancy,
mainly via their non-classical MHC I molecules (HLAE, HLAF, HLAG) expression. STMB play a key role in the induction of local
immune tolerance. Cell surface or STMB-bound non-classical MHCI molecules inhibit the killer activity of NK cells through
inhibitory receptors, suppress CTL activity and regulate the local CD4 Treg cell differentiation. STMB can also act on innate
immunity via the modification of neutrophil function and NET formation. uNKuterine natural killer cells; Tccytotoxic T cell;
Tactactivated T cells; Tregregulatory T cell; ThT helper cell; PMNpolymorphonuclear granulocyte, neutrophil.
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somewhat dominate over exosome secretion with a net
effect of a transient slightly inflammatory, hypercoagula-
tive state balanced by the counteraction of exosomes.
However, if the STBM production were highly enhanced
compared to exosome secretion, pathology occurs, being
the most classical example pre/eclampsia (526,527).
During normal pregnancy, the transient hypercoagul-
able state is well balanced. In contrast, pre-eclampsia is
characterized by excessive platelet activation, endothelial
damage and dysfunction and an increased tendency to
thrombosis. STBM express TF and the expression levels
are higher on pre-eclamptic vesicles (360). The increased
numbers of circulating STBM in the plasma of pre-
eclamptic women (along with the higher TF expression)
are proposed to comprise a substantial intravascular pro-
thrombotic stimulus in these patients (358360).
In summary, interactions of STB-derived EVs with
cells affect local angiogenesis; modulate the differentia-
tion and activity of immune cells at the fetomaternal
interface; have a direct effect on coagulation; and regulate
local and systemic inflammatory responses. On the basis
of these findings, STB-derived EVs may offer novel
diagnostic possibilities in the monitoring of pregnancy
progression and may also be considered in novel fertiliza-
tion strategies.
EVs in male reproduction
The multiple functions of EVs in semen physiology are
based on their ability to transfer molecules either to sperm
cells or to immune cells within the female reproductive
tract. Sperm cells come in contact with several types of
EVs, which can then promote their fertilizing ability by
modifying their molecular composition and behaviour
(Fig. 9). After sperm cells leave the testis, they recruit
membrane (P34H, ADAM7) and cytosolic (aldose reduc-
tase and sorbitol dehydrogenase) constituents from epidi-
dymosomes, that is, EVs released into the epididymal
duct by direct fission from the plasma membrane of
epididymal cells (528,529). Sperm cells later come in
contact with prostasomes. Prostasomes have been pro-
posed to play a role in the regulation of capacitation and
acrosome exocytosis (530,531). These are a complex series
of biochemical and biophysical changes that sperm cells
undergo in the female genital track to acquire fertilization
properties and reach the oocyte (530). Both capacitation
and the acrosome reaction involve protein phosphoryla-
tion, changes in cytosolic levels of Ca2 and cyclic
nucleotides, cholesterol transfer and remodelling of the
sperm plasma membrane domains (532). The function of
prostasomes in these processes is complex and both
inhibitory (533) and stimulatory effects have been reported
(534). In a unifying model (535) it was proposed that
prostasomes bind to sperm cells in the uterus early during
capacitation, inhibiting premature progression to late
capacitation events. Prostasomes may then ‘‘piggy-back’’
onto the sperm cell’s surface until approaching the oocyte
cumulus complex in the oviduct. There, prostasomes may
fuse with sperm cells, stimulating late capacitation events
and, ultimately, allowing the acrosome reaction.
Another main function of prostasomes is to protect
sperm cells from the female immune system on their way
to the ovum (536). Macrophages, neutrophil granulocytes
Fig. 9. EVs in the male reproductive tract and seminal plasma.
The epithelial cells of the epididymis produce a population of EVs that are thought to bud directly from the plasma membrane. These
vesicles, called epididymosomes, fuse with sperm cells to transfer proteins that contribute to the maturation of sperm cells. Epithelial
cells of the prostate also secrete EVs. These vesicles, sometimes termed prostasomes, have been suggested to originate largely from
MVB. Prostasomes are thought to interact with sperm cells in the female reproductive tract to facilitate them reaching the oocyte.
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and NK cells may all attack sperm cells (537,538).
Human prostasomes were able to inhibit phagocytosis
by monocytes and neutrophil granulocytes (539,540), as
well as interfere with lymphocyte proliferation. Also NK
cell activity was shown to be inhibited by prostasomes
and a role for the prostasomal protein CD48 (which is the
ligand for activating NK cell receptor 2B4) was proposed
(541). Furthermore, prostasomes may also protect sper-
matozoa against the complement pathway via their
constituents CD59 and CD46 (542,543). Finally, EVs in
human semen inhibited replication of sexually trans-
mitted retroviruses, but not herpes simplex viruses, in
target cells (544).
In conclusion, EVs in seminal plasma play an im-
portant role in fertilization by protecting sperm cells in
the female genital tract and by regulating their motility
and maturation. However, the composition of these EVs
is complex and the specific molecular processes and
mechanisms by which EVs help sperm cells in vivo on
their way to the oocyte have yet to be elucidated.
EVs function related to the embryonic development
EVs may also contribute to intercellular communication
during embryonic development. Here, the current evidence
of EV functions in central processes of embryogenesis,
such as morphogenetic gradients formation, cell migration
and the development of cellular polarity are reviewed.
EVs and morphogens gradients
One of the central processes of embryogenesis is the
coordination of cell positioning and fate acquisition in
response to the morphogens gradient (545). Certain
features of morphogen distribution, for example, specifi-
city towards certain target cells, dynamics of the distribu-
tion over long distances and the formation of intra- and
extracellular gradients, could not be explained by the
widely accepted model of gradient formation by passive
diffusion. The first hypothesis of an active morphogen
transport in Drosophila was suggested to be mediated by
means of membrane fragments called ‘‘argosomes’’
(546,547). Later on, argosomes were defined as exogen-
ously derived lipoprotein particles enriched with GPI-
linked proteins that support the transport of morphogens
through the epithelium (548). The function of EVs as one
of the secretion routes for functional Wnt proteins in vivo
was demonstrated by showing that Wnt proteins were co-
segregated from the supernatants of mammalian and
Drosophila cells, within the 100,000g pellets, and were
located on the outer membrane of EVs of approximately
80 nm diameter which also harboured CD63 and CD81
tetraspanins (549). Shuttle of functional Wnt proteins to
MVBs required ESCRT and was mediated by their cargo
receptor Evi Ykt6 protein, which regulates early/recycling
endosomes (549). Other lipid-modified morphogens such
as Hedgehog have also been shown to be secreted in an
ESCRT-dependent manner (550) in EVs travelling along
cytonemes in order to create a gradient in the tissue (551).
These data suggest that the distribution of morphogens
during embryogenesis is a complex process combining
different routes, such as passive diffusion of soluble
proteins and the active transport by lipoprotein particles
or by EVs. It remains to be established how the sorting of
morphogens between these routes is regulated and what
the specific impact of each particular route is in the
embryonic development.
EVs and tissue polarity
The contribution of EVs to the regulation of cell polarity
and developmental tissue patterning was initially sug-
gested by Lakkarajau and Rodriguez-Boulan (552).
However, until now only a few instances of indirect
evidence support the involvement of EVs in the regula-
tion of cell polarity during embryo- and organogenesis.
For instance, vesicular traffic was required for the
asymmetrical distribution of adenylyl cyclase during
collective head-to-tail cell migration in Dictyostelium
discoideum during which adenylyl cyclase accumulated
in the back of the cells within multi-vesicular bodies,
which then could be released as EVs and be tracked to
the direction of cell migration (553). In polarized cells,
EVs derived from the apical and basal membrane differed
in their content (554). Proteins involved in the regulation
of cell polarity, such as Rab11 (mediating exocytosis) and
syntaxin-3 (essential for establishing the polarized epithe-
lium) were located on the EVs and played important roles
in the regulation of vesicle release (555,556). In addition,
Notch signalling, essential for the determination of cell
polarization, could be modulated through delta-like 4
located on the EVs, supporting potential impact of EVs
on cell polarity (557).
In conclusion, EVs are likely to be involved in the
regulation of main routes of embryonic development,
including the regulation of morphogen gradients, collec-
tive cell migration and tissue polarity. However, this still
remains an emerging field with many unanswered ques-
tions, which need further investigation.
EV function related to tissue repair
Phenotype change and cellular plasticity are potential
driving factors in tissue regeneration and are being
increasingly explained by cellular communication via
EV-dependent delivery of RNA species (558). Stem cell
niches are considered areas of microenvironmental influ-
ence providing environmental aspects such as oxygena-
tion, position, mechano-transduction, soluble factors and
EVs mediating cellcell communication. It is likely that
regeneration is, in part, regulated by EV vesicle transfer.
Phenotype modulation with the expression of epithelial
prosurfactant B in marrow cells by lung-derived EVs and
engraftment of marrow cells after lung injury has been
shown as a novel mechanism for lung repair (559). A
report about the anti-apoptotic and cardio-protective
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effects of human embryonic stem cell-derived mesench-
ymal stem cell conditioned medium in a porcine model of
ischaemiareperfusion injury resulting in a 60% reduc-
tion in infarct size initiated an intensive search for the
responsible paracrine factors (500). Fractionation studies
revealed that the cardio-protective effect of conditioned
medium was exclusively exerted by the 1,000 kDa
fraction with sizes ranging from 100 to 220 nm; indicat-
ing that the active agent was a complex of multiple
components that might include proteins and lipids (500).
A subsequent study, using a myocardial ischaemia
reperfusion injury mouse model, confirmed that EVs
were indeed the large complexes responsible for the
cardio-protection (493). The evidence that tissue regen-
eration triggered by exogenous (stem) cells might depend
on the release of paracrine factors delivered by EVs,
rather than on stem cell trans-differentiation per se was
further supported by a report on hepatic regeneration
(560). EVs from human liver stem cells accelerated
morphological and functional recovery in a rat model
of 70% hepatectomy and mediated de novo expression of
human argonaute proteins in rat hepatocytes. This is
considered as definitive proof of horizontal mRNA
transfer between human and rat cells (560). EVs derived
from human adult MSCs have been found to protect
against ischaemiareperfusion kidney injury and en-
hanced survival in a model of lethal acute kidney injury
(187,501). In addition, in a clinical model of acute
myocardial infarction, lung resident MSCs efficiently
exerted pro-regenerative functions (490). Confirming
the paracrine nature of the MSCs supporting activity,
the supernatants of in vitro expanded MSCs have been
shown as sufficient in reducing myocardial infarct sizes
(500). Furthermore, the protective effect of EVs derived
from human peripheral blood-derived cells cultured
under angiogenic conditions was attributed to a miR-
NA-dependent reprogramming of resident renal cells and
was reversible with RNase or siRNA treatment (210).
EVs in bone calcification
From a historical perspective, investigations of the trans-
formation of cartilage into mineralized bone via extra-
cellular TFs dates back to at least the 1920s. The early
work of Anderson (4,561) supported the hypothesis
presented by Robison (562) that enzymes involved in
ossification are secreted from cells within the calcifying
tissue. First important results included the definite dis-
tinction of extracellular matrix vesicles (matrix EVs) from
lysosomes. From the presence of lipids at the calcification
sites, the existence of membranous structures was extra-
polated, and membrane-bounded vesicles were indeed
demonstrated in various mineralizing tissues by electron
microscopy. As a consequence, it was postulated that
matrix EVs contain enzymes that mediate a local increase
in orthophosphate and drive the formation of hydroyx-
apatite at the sites of matrix EVs accumulation or release
(561). Essentially, the purification strategy for matrix EVs
by sequential differential centrifugation has not changed
since 1970 (561), with the 100,000g pellet containing the
highest activity. Matrix EVs were later identified as
carriers of morphogenetic information and some of the
molecular details of bone morphogenetic protein (BMP)
transfer and VEGF, or bone sialoprotein (BSP) delivery,
were elucidated. Matrix EVs were found to stimulate
expression of alkaline phosphatase via BMPs, while VEGF
may promote capillary invasion of the growth plate (563).
Notably in this latter study, the first report of physiological
mineralization via matrix EVs with an initial release of
BMPs into the matrix and a subsequent breakdown of the
matrix EV membrane following mineral initiation was
described.
This seminal work has fundamentally influenced our
view of matrix EVs and much of the initially described
characteristics have stood the test of time. A current
model proposes matrix EVs to originate from the plasma
membrane of mineral-forming cells [see also (564)] and to
induce calcification during endochondral bone forma-
tion. Indeed, the proposed biogenesis of matrix EVs from
apical microvilli (565), as well as the lipid and protein
content of matrix EVs, strongly suggests a plasma
membrane-derived origin. However, in several studies,
vesicle biogenesis-related proteins were identified on the
surface of matrix EVs derived from aberrantly calcifying
cells that point to an endosomal origin.
Cardiovascular calcification and bone remodelling
share some fundamental regulatory principles and the
EVs involved are apparently differentially loaded with
specific cargo whose sorting and packaging is largely
influenced by the cellular context [reviewed in Ref. (566)].
It seems that matrix EVs, under pathological conditions,
may act as intercellular signalling modules in a manner
similar to exosomes rather than as ‘‘extracellular nuclea-
tion’’ sites under physiological conditions. Considering
the polarized release of matrix EVs into the extracellular
matrix and the proposed mode of action as a nucleation
site for calcification within the extracellular matrix, the
repertoire of proteins that are found in matrix EVs
appears both necessary and sufficient for these duties.
EVs function related to liver homeostasis
The liver is essential for metabolism and is involved in the
synthesis and clearance of blood and bile components,
storage and mobilization of lipids and carbohydrates and
response to external (e.g. diet, drugs) and internal (e.g.
endotoxins) stresses (567). Although this organ is formed
mostly by hepatocytes, it also contains other non-
parenchymal immune and non-immune cells that need to
communicate with each of them in order to elicit a proper
response to specific hepatic stimuli and insults. The
resident liver tissue macrophages (Kupffer cells), NK cells,
Biological properties of EVs and their physiological functions
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T cells and B cells are all members of the hepatic immune
system and are all important mediators in inflammation
(568). Among non-immune cells, the stellate cells, also
known as Ito cells, are involved in angiogenesis (569),
inflammation and fibrosis processes. All these cellular
populations, with their diverse physiological processes,
must be strictly coordinated to keep the liver healthy and,
subsequently, to maintain the right homeostasis of the
body. Increasing evidence supports the idea that EVs
mediate part of the intercellular communication among
different cell types. For example, it has been shown that
primary cultured hepatocytes are able to secrete EVs that,
based on density, structure and composition, show many
exosomal features (570). In addition, a comprehensive
proteomic study of these hepatocyte-derived EVs revealed
the presence of several members of cytochrome P450,
UridinediphosphateGlucuronosylTransferase (UGTs)
and Glutathione S-Transferase (GST) protein families,
supporting a role of these vesicles in the metabolism of
endogenous and xenobiotic compounds (570,571). Re-
cently, the RNAs present in these vesicles were character-
ized, showing that EVs from hepatocytes were able to
activate stellate cells to mediate a response to liver damage,
in an RNA-dependent manner (572). Moreover, EVs
derived from a sub-population of pluripotent/multipotent
resident liver cells were shown to accelerate the morpho-
logical and functional recovery of liver in partially
hepatectomized rats (560). This effect was lost when EVs
were treated with RNase, suggesting that RNA was also
involved in the process (560). Other hepatic cell types, such
as cholangiocytes, can also secrete EVs (277) and, by
means of transmission electron microscopy, EVs present in
the bile duct were shown to interact with the primary cilia
of cholangiocytes (573), supporting a role in intercellular
communication in this cellular system. Biliary EVs
secreted by cholangiocytes contribute to the inactivation
of ERK kinase signalling (278), a pathway associated with
cholangiocyte proliferation (574). Cholangiocytes and
myofibroblastic hepatic stellate cells released EVs contain-
ing active Hedgehog ligands in response to platelet-derived
growth factor, which, in the acceptor cells, activated
Hedgehog signals that may stimulate angiogenesis (277).
Although studies on hepatic EVs have been limited to
date, they support an important role of these vesicles in
maintaining liver homeostasis. Further research in other
liver resident cells (e.g. hepatic sinusoidal cells) and
studies involving the co-culture of combinations of
different cell types in controlled conditions are required
to further unravel the physiological role of the network of
EVs established in the liver.
EVs in the nervous system
The major task of the nervous system is the integration of
incoming information and generation of an output,
coordinating the functions of the different organs and
tissues in the body. Systemic signal processing not only is
achieved by synaptic cross-talk among electrically active
neurons, but also depends on non-synaptic neuronal
interaction and intense communication between neurons
and glial cells. Recent research provides compelling
evidence that the exchange of EVs may be a common
mode of neural cell communication. Cultured neurons and
the different types of glial cells release EVs [reviewed in
Ref. (575578)]. Furthermore, EVs of distinct size and
origin can be detected in the CSF (see EVs in Cerebrosp-
inal Fluid section), the drainage system of the brain
(281,282). Several studies suggest that EVs possess
the ability to cross the bloodbrain barrier in both
directions, although the route of transfer remains unclear
(324,579,580). EVs were shown to enter the brain par-
enchyma at the choroid plexus and to mediate folate
import into the brain (581). Notably, inflammatory con-
ditions, often associated with a leaky bloodbrain barrier,
facilitated the entry of peripheral EVs into the brain
resulting in genetic modulation of the target cells of the
CNS (582). EVs released from neurons have been im-
plicated in the transfer of biomolecules across synapses
and were suggested to mediate synaptic plasticity in
vertebrates and invertebrates. In rodents, glutamatergic
synaptic activity triggered the release of EVs largely from
somato-dendritic (post-synaptic) sites (575,583). These
EVs contained neurotransmitter receptor subunits, which
led to the suggestion that release of EVs may affect the
local elimination of these receptors from post-synapses
and, thus, may modulate synaptic strength as part of a
process termed homeostatic synaptic scaling. Moreover,
neuronal EV released in activity-dependent fashion car-
ried the synaptic-plasticity-associated protein MAP1b
and miRNAs (584) and preferentially interacted with
target neurons at pre-synaptic terminals (575,583,585).
At the Drosophila larval neuromuscular junction, EVs
modulated synapse expansion by mediating the transmis-
sion of Wnt-signalling molecules, as well as the transfer
of synaptotagmin 4 from pre-synaptic motor neurons
to post-synaptic muscles (586,587). In Caenorhabditis
elegans, it was demonstrated that EV budding from the
cilia of sensory neurons mediated communication even
between different animals and influenced mating related
behaviour (588).
Moreover, all types of macroglia and microglia secrete
EVs in the form of exosomes or microvesicles. Microglia,
which are phagocytic cells contributing to CNS tissue
homeostasis, respond to ATP-mediated P2X7 receptor
activation by shedding EVs from their plasma membrane.
Intriguingly, microglia-derived EVs appeared to modu-
late neurotransmission at excitatory glutamatergic as well
as inhibitory GABA-ergic synapses largely by lipid-
mediated signalling (578,589,590). In addition, microglial
EVs were proposed to propagate inflammation in the
CNS, since they carried the pro-inflammatory cytokine
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IL-1b and were increased in CSF during inflammation
(591). Conversely, microglia mediated the immunologi-
cally silent clearance of EVs originating from other CNS
cells (such as oligodendrocytes); at least under physiolo-
gical conditions (98,592).
Moreover, it has been demonstrated that EVs may
participate in reciprocal communication between myeli-
nating oligodendrocytes and neurons. Electrically active
neurons could trigger the release of oligodendroglial EVs
by neurotransmitter signalling and, furthermore, inter-
nalized these EVs by endocytosis (593). Hence, target
neurons directly modulated the availability of oligoden-
droglial EVs, following the principle of ‘‘delivery on
demand.’’ Neurons that received oligodendroglial EVs
were more resistant to cell stress, indicating that oligo-
dendroglial EVs provided trophic support to target
neurons and mediate neuroprotection. Consistently, oli-
godendroglial EVs activated pro-survival signalling path-
ways and modulated gene expression in target neurons
(594). Likewise, Schwann cells in the peripheral nervous
system secreted EVs that were internalized by axons,
providing local axonal support. Schwann cell-derived
EVs were able to enhance axonal regeneration after nerve
damage (595). EVs that enter the CNS from the peri-
phery may also exhibit regenerative functions: MSC-EVs
were shown to transfer neuroregenerative miRNAs to
astrocytes and neurons in a rat model of stroke (596).
Furthermore, serum EVs harvested from youthful mice
were suggested to enhance myelination as well as
remyelination (597).
In summary, EVs have been established as novel
players in neural cell communication with versatile
physiological implications, both in the developing and
the adult nervous system. The role of EV-mediated
horizontal transfer of RNA in intercellular gene regula-
tion and the local phenotypic adaptation of neural cells
remains an exciting open question in neuroscience.
Furthermore, substantial efforts are being invested into
deciphering the putative role of EVs in the spreading of
neuropathological agents in neurodegenerative diseases
as well as in promoting the growth of brain tumours
[reviewed in Ref. (598,599)].
EVs in lower organisms
Parasites have plagued humans throughout the world for
more than 150,000 years (600). It is currently believed that
there are close to 400 species affecting humans, of which
approximately 90 are responsible for great clinical burden
and death (601). The use of secretion systems is an
essential biological process exploited by pathogenic micro-
organisms to promote survival. In this context, the study
of EVs released by pathogens is a new and exciting field
that may realistically contribute to a better understanding
of the pathogenic process (602,603) (Fig. 10) and provide
alternate control strategies for the 2 major groups of
parasites, the helminths (worms) and the parasitic proto-
zoa (604606) (Fig. 10). The half-life of these EVs can
vary, they can either be quickly broken down, existing only
in the immediate space of the pathogen; or, they can
persist appearing in many biological fluids such as urine or
blood (100). This potential for persistency enhances their
capacity to interact with target cells in ways impossible for
free soluble molecules functioning as extensions of the
pathogen (602). Moreover, their membranous nature
enables their fusion with/uptake by target cells, potentiat-
ing the horizontal transfer of cargo molecules including
proteins and RNA (100). These pathogen-derived EVs,
therefore, have the potential to mimic the characteristics of
the host EVs.
Helminths
Helminths can be divided into 2 major groups known as
the nematodes (roundworms) and the Platyhelminthes
(flatworms), this latter composed of cestoda (tapeworms)
and trematoda (flukes). Together, these are responsible
for a large burden of disease and socio-economic losses,
as hundreds of millions of peoplemostly in areas of
extreme povertyare infected (600). Early reports sug-
gesting the existence of EVs in helminths came from
TEM studies of tegument of flukes Schistosoma mansoni
and Fasciola hepatica (607,608). Later, protein analysis of
the tegument of Schistosoma spp. revealed the presence of
typical ‘‘exosome proteins,’’ suggesting that helminths
could actively secrete EVs (609,610). Recently, the
existence of exosome-like EVs in the parasitic intestinal
trematode Echinostoma caproni and the liver fluke
Fasciola hepatica has been confirmed (611). This report
constitutes the first description of EVs in parasitic
helminths, identifying 51 and 79 parasitic proteins from
E. caproni and F. hepatica, respectively. More than half of
the proteins identified had previously been described in
the secretome of other parasitic trematodes (612). These
data suggest that EVs may constitute the primary
mechanism for protein export in trematodes.
In contrast to trematodes, little is known about the
presence of EVs in parasitic nematodes. Yet, preliminary
studies have identified EVs in the parasitic nematode
Heligmosomoides polygyrus, exhibiting immunomodula-
tory activity (613,614). Recently, the presence of ‘‘atypical
secreted’’ proteins, including 14-3-3 and serpin, was
described in the Ascaris suum larval proteome, suggesting
that they were secreted in EVs (615).
As highlighted in the RNA composition section, EVs
are also gaining attention since they act as a novel RNA
shuttle mechanisms capable of signalling messages to
other cells and as new powerful diagnostic markers of
disease (16). miRNAs were isolated from EVs from the
parasitic trematode Dicrocoelium dendriticum (616). In
addition, H. polygyrus derived miRNAs and Y RNAs
were shown to be transported into mammalian host cells
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Fig. 10. EVs in parasitic diseases.
Secretion of EVs has been described for both helminths and parasitic protozoa. In helminths, they serve as mechanism for protein and
miRNA export and host manipulation. In parasitic protozoa from the kinetoplastids family, EVs released by Leishmania spp. are able
to induce specific recruitment of neutrophils to the site of infection. They are also taken up by phagocytic cells, enabling the delivery of
immunomodulatory proteins contributing to the creation of a permissive environment for the infection. In T. cruzi, EVs contribute to
the stabilization of the C3 convertase disturbing the functioning of the complement system. Regarding Apicomplexa in malaria,
circulating levels of EVs rise during human infections and in rodent models, while exosomes derived from reticulocytes induced
protection upon immunization in a murine model. Also, exosomes from malarial infections were able to induce parasite sexual
development. Other obligate intracellular parasitic protozoa are Toxoplasma gondii and Trichomonas vaginalis. EVs isolated from
dendritic cells and primed with Toxoplasma antigens conferred protection upon immunizations being a proof-of-concept of EVs as
therapeutics agents. In trichomoniasis EVs increased virulence by inducing parasite attachment to cervical epithelium, thus facilitating
host cell colonization.
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via EVs, where they regulated host genes associated with
immunity and inflammation and suppressed the innate
type 2 response in vivo (616,617) suggesting that this may
be a common feature for parasitic helminths (618). The
function and diagnostic potential of such RNAs needs
further investigation.
Parasitic protozoa
Close to 70 species of parasitic protozoa affect hundreds
of millions of humans annually causing a wide spectrum
of poverty-related diseases such amoebiasis, malaria,
African and American trypanosomiasis and leishmania-
sis. As in helminths, research on EVs in parasitic
protozoa is gaining attention, especially in hostparasite
interactions (604606). For this reason, we briefly dis-
cuss EVs in the context of 2 major groups, that is,
kinetoplastids and apicomplexa.
Kinetoplastids
Trypanosoma cruzi and Trypanosoma brucei. Trypano-
somes is a complex group of unicellular parasitic proto-
zoa belonging to the order kinetoplastida, which often
require intermediate hosts to complete their complex life
cycle (619). In humans, trypanosomes cause a variety of
diseases such sleeping sickness caused by Trypanosoma
brucei (T. brucei) and Chagas disease caused by
Trypanosoma cruzi (T. cruzi). The first description of
the shedding of EVs from trypanosomes was elegantly
shown by TEM studies of T. cruzi where the release of
2080 nm EVs containing parasite antigens was evident
(620). The proteomics analyses of EVs from T. cruzi have
expanded the list of known parasite proteins, including
members of the transialidase multigene family, proteases
and cruzipain, among many others (621). Similar to T.
cruzi, T. brucei actively secretes EVs containing parasite
proteins that are apparently involved in intercellular
communication with the host (622). Interestingly, a
significant proportion of proteins in the secretome lack
a transit peptide, suggesting that they are not secreted
through a classical sorting pathway. To clarify this, EVs
were isolated and characterized from secreted material as
well as from infected rat sera, confirming an active
exocytosis process beyond the flagellar pocket (622).
The secretion of proteins via the EV pathway may have
several advantages for trypanosomes, such as delivering
an avalanche of new epitopes to overwhelm the host
immune system or to establish a communication link
between parasites as a survival strategy. Also in EVs
derived from T. cruzi, proteins associated with virulence
where also detected (621,623,624) as a clear indication of
the potential of these EVs as immunomodulatory agents.
Moreover, T. cruzi were found to induce EV release from
infected blood cells. Those EVs formed a complex with
the complement C3 convertase on the T. cruzi surface,
leading to its stabilization and inhibition and resulting in
increased parasite survival (416).
Leishmania spp. Leishmania are the etiological agents of
leishmaniasis. This parasite adapted to survive and
proliferate in the shadow of the immune system thriving
in the inhospitable environment of the macrophage
phagolysosome. Recent emphasis has been given to the
possible role of EVs in this process (625). Leishmania EVs
were originally reported in L. donovani promastigotes
grown in CM (626). The size, density and protein content
of recovered EVs are consistent with their identification
as exosomes (626). Nonetheless, the detection of EVs of
larger size with protein content not traditionally asso-
ciated with exosomes suggests the existence of different
types of EVs (627). The release of EVs seems to be
constitutive, being detected in culture supernatant of
logarithmic and stationary promastigotes in axenic
growth (627). Moreover, physiological stress conditions
such as temperature shift to 378C (626,628), acidic pH
(626), death-inducing agents (627) and starvation (629)
are capable of increasing EVs release in vitro. Therefore,
the constitutive nature of EVs release and their involve-
ment in the response to external stimuli suggests that they
might be involved in significant biological processes that
are still unreported (627). In fact, most of the reports on
Leishmania EVs are related to their involvement in the
infectious process, overlooking their possible roles in
housekeeping, communication, death and differentiation.
The capacity of Leishmania EVs to function as
extensions of the parasite enabling close and long-range
immunomodulation was shown in vitro. The EVs from L.
donovani inhibit pro-inflammatory cytokine production
(TNF-a), while promoting immunosuppressive cytokine
production (IL-10) in human monocytes (630). Interest-
ingly, consistent with an immunosuppressive profile, it
was shown that EVs treatment also hampers the in vitro
differentiation of naı¨ve CD4 T cells into IFN-g Th1 cells
in a cargo-dependent manner (630). Moreover, the few
reports that addressed the in vivo properties of these EVs
also seem to be consistent with a permissive infection
(630). The vesicle components responsible for these
immunomodulatory properties are, understandably, sub-
jects of great interest as Leishmania EVs are capable of
delivering their content into target cells (626). Interest-
ingly, all the known Leishmania proteins shown to
translocate into the macrophage cytosol were found in
Leishmania EVs cargo (626,627). The possibility of
virulence factor delivery mediated by EVs was clearly
shown using a protease (GP63) that is associated with
direct modulation of host signalling in the precocious
stages of infection (631,632). Using EVs recovered from
L. major gp63 -/-, it was demonstrated that their
immunomodulatory capacities were substantially redu-
ced (633). Moreover, GP63 delivery by EVs was also
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associated with in vivo and in vitro downregulation of
specific miRNAs in hepatocytes, facilitating liver infec-
tion (634). The capacities of EVs to influence the
outcome of the infection might not be restricted to the
delivery of virulence factors. In fact, EVs are also capable
of cell-specific recruitment (633), possibly contributing to
the cellular environment in the initial inoculum. There-
fore, as consequence of the delivery of immunomodula-
tory molecules and also the direct interaction with target
cells, Leishmania EVs are expected to be significant
players in the precocious steps of infection enabling a
permissive environment for the parasite.
Apicomplexa
Apicomplexa is one of the largest groups of para-
sitic protozoa with more than 5,000 species, including
human parasites such as Plasmodium spp. (malaria),
Cryptosporidium spp. and Toxoplasma spp. in humans,
and animal parasites such as Babesia spp. in cattle and
Eimeria spp. in poultry. Apicomplexa are characterized by
having a unique organelle of algal origin known as the
apicoplast. Studies on EVs in Apicomplexa have started
to shed light into the complex signalling pathways
mediated by these vesicles, which act as intercellular
communicators between hosts and parasites.
Malaria is the most prevalent parasite worldwide and
responsible for close to 300 million clinical cases and 1
million deaths annually; mostly in children under 5 years
old. Both exosomes and microvesicles have previously
been described in human and rodent malaria parasites.
Specifically, EVs have been detected in the peripheral
blood of P. falciparum as well as P. vivax patients and
seem to be involved in systemic inflammation (635637).
In the case of P. falciparum, the presence of EVs was
associated with severe malaria suggesting that they play a
role in malaria pathogenesis (636). Interest in the studies
of EVs in malaria received further impetus after it was
demonstrated that EVs derived from reticulocytes in a
rodent malaria model contained parasite proteins and
were able to modulate induced protective immune
responses upon a lethal challenge (376). More recently,
2 independent studies have demonstrated that EVs
secreted by P. falciparum-infected red blood cells act as
intercellular communicators (638,639). Remarkably, both
studies suggest that the transference of exosome-like
vesicles and microvesicles to other infected red blood
cells induces gametocytogenesis, providing the parasite a
route to escape a hostile environment.
In addition to malaria, studies have reported on EVs of
other apicomplexa and unicellular parasites such as
Cryptosporidium parvum (640) and T. gondii (641) (ob-
ligate opportunistic intracellular pathogens recognized
as a major cause of diarrhoea in AIDS and immunode-
pressed patients), Giardia lamblia (642) (responsible
for diarrheal illness) and Trichomonas vaginalis (624)
(causing the most prevalent sexually transmitted disease).
In summary, although study on the molecular compo-
sition and function of EVs in parasites is a young
research field, the data gathered so far from different
hostparasite interactions, clearly indicates the role of
EVs in intercellular communication, immune evasion
mechanisms and establishment of chronic infections. In
turn, these data will hopefully bring new insights into the
pathophysiology of human parasitic diseases to guide
rationale efforts in developing novel control strategies,
implemented as new diagnostics, treatment tools and
vaccines (618).
Bacterial EVs
EVs are produced by both gram-negative and gram-
positive bacteria (643). Gram-negative bacteria possess 2
phospholipid membranes. The inner (cytoplasmic) mem-
brane is the main diffusion barrier, but the cells are
protected by the additional peptidoglycan cell wall
situated in the periplasma and the outer membrane.
The outer membrane is the interface of the gram-negative
bacteria with its environment and the extracellular lipid
leaflet contains membrane lipids with extensive sugar
modifications, the lipopolysaccharides (LPS). By an
outward budding of the outer membrane, EVs are
produced with a diameter in the range of 20250 nm
(Fig. 11). The molecular mechanism of vesiculation is not
completely understood, but it appears to be an essential
and conserved biological process of gram-negative bac-
teria (644). During the genesis of outer membrane
vesicles (OMV), periplasmatic components are entrapped
into their lumen. Analysis of OMV suggests that their
protein and lipid composition is not random (645), so
that the cargo of these OMV (either in the lumen or
attached on the outside) is regulated by mechanisms not
yet understood.
In contrast to gram-negative bacteria, gram-positive
bacteria are surrounded only by a single membrane.
Although the mechanism of vesicle formation is currently
unclear, the membrane and the lumen of vesicles of gram-
positive bacteria are thought to be derived from the
cytoplasmic membrane and the cytoplasm, respectively
(646).
These distinct bacterial secretion pathways enable cells
to deliver a multitude of effector molecules at a higher
concentration over long distances while encased in a
protective membranous sphere (644,647649). The bac-
terial EV content may be delivered into animal, plant and
bacterial cells by membrane fusion and/or internalization
and its delivery can be targeted by molecules attached at
the outside of the vesicles.
Bacterial EVs perform several functions, inclu-
ding molecular transport, mediation of stress response,
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biofilm formation and the influence on hosts, which are
described in more detail in the following sections.
Transport & delivery
OMVs have been shown to act as trafficking vehicles for
hydrophobic molecules such as the Pseudomonas signal-
ling molecule PQS, thereby playing important roles in
intra-species cellcell communications and quorum sen-
sing (650,651). In addition, OMVs could facilitate the
horizontal transfer of antibiotic resistance between bac-
teria (652,653) in 2 different ways, that is, by intra- or
inter-species transfer of resistance proteins (i.e. b-lacta-
mase) to neighbouring cells (654,655) or by lateral
transfer of resistance genes following the fusion of the
OMVs with the recipient cell membrane (656658). Our
current knowledge of bacterial OMVs is focused on the
pathogenic bacteria, which can specifically deliver toxins
and virulence factors to the eukaryotic target cells by
OMVs. It was recently shown that the gram-positive
bacterium Bacillus anthracis produced EVs containing
anthrax toxin (659).
In contrast, the physiological roles of commensal-
derived OMVs remain yet largely unexplored. One mem-
ber of human microbiota, Bacteroides fragilis, was shown
to secrete polysaccharide A capsular antigen (PSA)-
containing OMVs that could trigger a TLR2 mediated
signalling in DCs, resulting in production of the immu-
noregulatory cytokine IL-10 which resulted in the matura-
tion of T regulatory cells (660), implicating OMV as
important mediators in the establishment of mutualism.
Stress response
OMV production is an indispensable bacterial survival
strategy in response to environmental stress. Stressors
such as heat shock can lead to the accumulation of
misfolded proteins within a cell, thus promoting toxicity.
Misfolded proteins may be sequestered in OMVs and
exported out of the cell (661). OMVs may also act as
decoys to protect bacteria from complement components
(662), long-chain alcohols, metal chelators (663) and anti-
microbial peptides (664).
Biofilm
Biofilm formation is an alternative bacterial survival
strategy that enables protection and persistence of a
bacterial community. In biofilms, bacteria live as a multi-
cellular community in an extracellular matrix. OMVs play
a prominent role in the formation and maintenance of this
extracellular matrix (665). Biofilm OMVs mediate adhe-
sive interactions contributing to the biofilm formation and
stability, the nutrient delivery to the cells embedded deep
within the matrix and the long-range transport of effector
molecules/neutralizing agents beyond the matrix bound-
aries, contributing to virulence and antibiotic resistance
(663,665669). OMVs can also function as offensive tools,
lysing competitor bacteria (670,671). Such a strategy
would be particularly suitable for adaptation to new
Fig. 11. Biogenesis of an outer membrane vesicle (OMV).
Initialized by outward bulging of the outer membrane, vesicles bud off the gram-negative cell and are then termed OMVs.
The membrane of the vesicle is derived from the outer membrane and the lumen contains proteins and other biomolecules from the
periplasma.
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ecological niches and is also followed by other organisms
(as described above for parasites).
Interaction with the host
Both symbiotic and pathogenic bacteria can interact with
human cells by means of OMVs. In particular, the human
bacterial flora consists mainly of anaerobic bacteria that,
in healthy individuals, create a symbiotic relationship
with the host, since these bacteria play important
physiologic roles such as repression of the growth of
pathogenic microorganisms, differentiation of the epithe-
lial barrier, regulation of nutrition and metabolic func-
tions and stimulation of innate immunity functions.
Collectively, the human bacterial flora colonizes some
organs of the human body; primarily conjunctiva,
oropharyngeal cavity, upper respiratory tract, gastroin-
testinal and urogenital organs and skin, where they exert
their functions by interacting with different cell types.
Although the first barrier of cells with bacteria are the
epithelial tissues, the OMVs produced by these bacteria
may ‘‘cross’’ this epithelial barrier and interact with some
of the connective tissue cells, primarily immune cells
(672). Hence, in both the epithelium and the connective
tissue of skin and mucosa there are heterogeneous
populations of cells that are putative targets and effectors
of OMVs. However, a comprehensive view of how the
OMVs of the bacterial flora interact with human cells is
not yet available, and so far, there have been no published
studies about the effects of OMVs in some anatomical
locations, such as the skin and conjunctival, urethral,
vaginal and large bowel mucosae. Here, we have sum-
marized the few studies that have addressed the direct
OMV interaction with human cells (Table III). This table
highlights the current knowledge  and also lack of
knowledge  on the physiologic role of OMVs produced
by bacteria found in humans and should encourage
further studies in this field.
EVs derived from virus-infected cells
Several lines of evidence indicate that viruses can modify
both the quality and the quantity of EVs released by
infected cells and that these EVs can be beneficial for
either the host or the pathogen [reviewed in Ref. (673)].
Epstein Barr virus (EBV), herpes simplex virus and HIV
belong to the most intensively studied viruses with respect
to EV release. EVs released by EBV-infected B cells were
shown to deliver the EBV latent membrane protein 1
(LMP1) protein to surrounding uninfected cells, thereby
contributing to virus latency and tumour progression
(674,675). In addition, EVs derived from EBV-infected
cells were shown to carry EBV-encoded mature miRNAs
in their lumen (676,677). Upon EV-mediated delivery to
uninfected cells, EBV miRNAs were shown to be func-
tional and to mediate translational repression of their
target genes (676). In addition, the EBV-encoded miRNA
miR-BART15 was released in the EVs from EBV-infected
B cells which inhibited the NLRP3 component of the
inflammasome in EV-targeted uninfected cells (678). HIV
has also been shown to encode its own miRNAs. A
prominent HIV miRNA, the trans-activation response
element (TAR), was found to be present in EVs secreted
from HIV-infected cells. Exposing uninfected cells to EVs
derived from HIV-infected cells resulted in an increased
susceptibility to HIV infection, through TAR-regulated
inhibition of apoptosis in the recipient cells (679). Also,
the presence of HIV co-receptors in EVs derived from
HIV-infected cells may confer an increased susceptibility
to infection in recipient cells that are otherwise non-
permissive (93). Infection of hepatocytes with hepatitis
C virus led to the incorporation and export of viral
genomic and sub-genomic RNA sequences in EVs.
Targeting of these EVs to non-permissive plasmacytoid
DCs induced a strong interferon response in these cells,
which contributes to the antiviral response (680).
Interestingly, viral genomes from coxsackie virus B1,
Hepatitis A and C viruses were shown to be packaged in
EVs for release in the extracellular milieu [reviewed in Ref.
(681)]. Based on these observations, it can be hypothe-
sized that EVs could serve as vehicles that mediate
intercellular transmission of non-enveloped viruses. The
use of cellular secretion and vesicular trafficking and
targeting pathways may allow viruses to disseminate and
gain access to a pool of potential target cells that are
otherwise non-permissive for virus entry, while escaping
immune surveillance (682).
Function of EVs in plants
To date, the pathway of EV release has not been directly
dissected in plants. Indirect evidence does exist, however,
that vesicle exocytosis is involved in normal plant
physiology (Fig. 12).
Apoplastic fluid of sunflower seeds was reported to
contain 50200 nm phospholipid-containing vesicles of
exosomal appearance (683). The protein profile of these
EVs was distinct from that of whole sunflower extract
and also contained a protein showing 68% identity with
human Rab11a GTPase, a mammalian exosome protein
identified in several proteomic studies (92) which pro-
motes the docking and the fusion of MVBs with the
plasma membrane (556,684). Rab11 GTPases were also
involved in secretion and recycling of cell wall compo-
nents in tomato (685) and polarized pollen tube growth
in tobacco (686). Here, coordinated Rab11 GTPase
activity was required for essential membrane trafficking,
protein secretion and cell wall modification during fruit
ripening.
Direct evidence for fusion of MVBs with the plant
plasma membrane has so far come primarily from stu-
dies of fungal infection. Vesicle-like bodies or granules
containing anti-microbial compounds were shown to
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Table III. A summary of 14 papers selected from 180 Pubmed papers published between 1991 and 2013, on the subject of ‘‘outer
membrane vesicles (OMVs),’’ published in international journals that studied, using either in vivo or in vitro models, the direct effects
on OMVs on human cells
Anatomical site Predominant bacteria (genera) Studies about OMV interaction with human cells Ref.
Respiratory tract
mucosa
Corynebacterium
Moraxellaceae
Pseudomonas
Staphylococcus
OMVs from Moraxella catarrhalis may bind to lipid raft domains
in alveolar epithelial cells and be internalized after interaction
with Toll-like receptor 2. These OMVs may also modulate the
pro-inflammatory response in pharyngeal epithelial cells.
(701)
Pseudomonas aeruginosa (PA) secretes OMVs containing a
bacterial virulence factor Cif (PA2934), which inhibits cystic fibrosis
transmembrane conductance regulator-mediated chloride
secretion and thereby reduces the mucociliary clearance of the
pathogen.
(702)
Cif (PA2934) secreted in OMVs by PA selectively increases the
amount of the ubiquitinated transporter associated with antigen
processing and its degradation in the proteasome of airway
epithelial cells. Cif inhibits MHC class I antigen presentation.
(703)
Oropharyngeal
mucosa
Aggregatibacter
Haemophilus
Lactobacillus
Moraxella
Neisseria
Porphyromonas (a)
Staphylococcus
Streptococcus
Porphyromonas gingivalis (PG)a OMVs significantly inhibit the
proliferation of cultured gingival fibroblasts and endothelial cells
in a dose-dependent manner. Data suggest that PG OMVs
contribute to chronic periodontitis.
(704)
Moraxella catarrhalis is endocytosed and killed by tonsillar B cells,
whereas its OMVs have the potential to interact and activate B cells
leading to bacterial rescue.
(705)
OMVs of PGa cause cell detachment when added to a monolayer of
oralsquamous epithelial cells; the effect was inhibited by
preincubating OMVs with anti-gingipain antiserum. Hence, PG
OMVs may contribute to tissue destruction in periodontal diseases.
(706)
OMV proteins of Aggregatibacter actinomycetemcomitans are
internalized in gingival fibroblasts via a mechanism of OMV
fusion with lipid rafts, inducing a cytolethal effect. OMVs
deliver cytolethal toxin and additional virulence factors into
periodontium.
(707)
Haemophilus influenza (NTHI) OMVs can bind to pharyngeal
epithelial cells, resulting in a time- and temperature-dependent
aggregation on the host cell surface, with subsequent
internalization and secretion of IL8 and LL-37.
(708)
Stomach mucosa Helicobacter
Lactobacillus
Staphylococcus
Streptococcus
Low doses of Helicobacter pylori (HP) OMVs from cag PAI
toxigenic and cag PAI non-toxigenic strains increase
proliferation of gastric epithelial cells. At higher doses, effects
were growth arrest, increased toxicity and interleukin-8 (IL-8)
production.
(709)
Treatment with OMV isolated from a toxigenic HP strain (60190)
induces an increased micronuclei formation in gastric epithelial
cells. OMV-mediated delivery of VacA to the gastric epithelium may
constitute a new mechanism for HP-induced gastric cancer.
(710)
HP OMVs are equipped with all the molecules required to interact
with gastric epithelial cells in a manner not dissimilar from the
intact pathogen.
(711)
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aggregate directly beneath sites of fungal attack, for
example, upon attempted entry of pathogenic pow-
dery mildew fungus Blumeria graminis f.sp. hordei (Bgh)
into barley leaves (687). By TEM, the outer membrane
of MVBs was observed to be attached to the plasma
membrane. The observation led to the proposal that
MVB-mediated exocytosis of vesicles into the paramural
space (situated between the plasma membrane and cell
wall) of plant cells occurs analogous to animal exosome
secretion; presumably such EVs participate in the defense
response to pathogens.
Evidence also exists that vesicular exocytosis may be
involved in the double fertilization process of Arabidopsis
(688). During fertilization, one sperm fuses with the egg
cell, whereas a second sperm cell fuses with the central
cell. An egg cell-specific transcript, EC-1, is accumulated
in spherical vesicle structures within the unfertilized egg
cell. Upon sperm arrival, EC-1-containing vesicles are
exocytosed. This exocytosis is a prerequisite for the
second-round fertilization of the central cell and, hence,
reproductive success. Furthermore, a cross-kingdom
communication between plants and mammals may be
facilitated by EVs. Rice-derived miR168 were reported to
be elevated in Chinese individuals and this miRNA was
shown to enter the circulation of rice-fed mice enclosed in
EVs. Upon circulation, miR168 could down-regulate
low-density lipoprotein receptor adaptor protein 1
(LDLRAP1) in mouse liver with concomitant increase
in plasma low-density lipoprotein (LDL) levels (689). A
different study, however, found little evidence for general
uptake of dietary plant xeno-miRNAs in the blood
stream of pig-tailed macaques (690). Future studies
may help to establish how widespread the phenomenon
of EV-mediated cross-kingdom communication is.
Anatomical site Predominant bacteria (genera) Studies about OMV interaction with human cells Ref.
HP OMVs are internalized in gastric epithelial cells via various
pathways, including clathrin-mediated endocytosis. VacA toxin
enhances the association of HP OMVs with the cells and the
presence of the toxin may allow vesicles to exploit more than one
pathway.
(712)
Helicobacter suisb OMVs were identified as a possible delivery route
of g-glutamyl transpeptidase to lymphocytes residing in the deeper
mucosal layers.
(672)
Small bowel
mucosa
Bifidobacterium
Clostridium
Enterobacterium
Lactobacillus
Staphylococcus
Streptococcus
Campylobacter jejuni (CJ)b OMVs possess cytotoxic activity and
induce a host immune response from intestinal epithelial cells
(IECs), which was not reduced by OMV pre-treatment with
proteinase K or polymyxin B prior to co-incubation with IECs.
Pre-treatment of IECs with methyl-beta-cyclodextrin partially
blocks OMV-induced host immune responses, indicating a role for
lipid rafts in host cell plasma membranes during interactions with
CJ OMVs.
(713)
Large bowel
mucosa
Bifidobacterium, Clostridium,
Enterobacteria, Lactobacillus,
Streptococcus,
Staphylococcus
No studies
Urethral mucosa Corynebacterium,
Staphylococcus
No studies
Vaginal mucosa Lactobacillus No studies
Conjunctival
mucosa
Corynebacterium,
Pseudomonas, Staphylococci,
Streptococcus
No studies
Skin Staphylococcus,
Streptococcus
No studies
Studies on the OMV stimulation of human peripheral blood cells and studies on the use of OMVs in vaccination were omitted, since we
focused here on the physiologically relevant interaction of EVs produced by the bacterial flora with the tissues representing the first
‘‘barrier’’ of the human body. aFacultative intracellular pathogen. bPathogenic for Homo sapiens.
Investigated cell type is highlighted in bold.
Table III (Continued )
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Concluding remarks
The data obtained so far and reviewed here has already
established EVs as novel players in various cell communica-
tion systems. These EVs have displayed versatile physiolo-
gical functions and are likely to be involved in the regulation
of main routes of signalling and intercellular information
transfer between different cell types, possibly even cross-
kingdom. Thus, in further developing the great scope of
physiological cell system compositions and dynamics 
previously understood to be comprised of different tissue
stroma, body fluids and soluble mediators  the presence
and functional modalities of EVs should now be considered
and paradigms redefined. The biology of EVs  their
molecular composition and function, targeting and uptake
mechanisms  is still a young research field, to some extent
awaiting new technological advances for the isolation and
characterization of complex mixtures including very small
vesicles. Despite this, research to date has clearly highlighted
the role of EV-mediated horizontal transfer of bioactive
proteins, lipids and nucleic acids in gene regulation, local
phenotypic adaptation and immune evasion, undoubtedly
opening exciting perspectives for clinical and therapeutic
advances. More extensive research to establish a deeper
understanding of the physiological relevance of EVs in
different homeostatic changes is now warranted.
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